Alimera Sciences (ALIM) 10-K 3 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 01, 2017	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ALIMERA SCIENCES INC
Entity Central Index Key	1,267,602
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 45,721,956
Entity Common Stock, Shares Outstanding		64,862,904

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 30,979	$ 31,075
Restricted cash	31	37
Accounts receivable, net	13,839	9,799
Prepaid expenses and other current assets	2,107	2,696
Inventory, net (Note 4)	446	1,552
Total current assets	47,402	45,159
Property and equipment — at cost less accumulated depreciation	1,787	2,553
Intangible asset, net	20,604	22,549
Deferred tax asset	436	223
TOTAL ASSETS	70,229	70,484
CURRENT LIABILITIES:
Accounts payable	4,986	4,002
Accrued expenses (Note 7)	3,758	3,911
Derivative warrant liability	188	0
Note payable (Note 9)	0	31,786
Capital lease obligations	191	234
Total current liabilities	9,123	39,933
NON-CURRENT LIABILITIES:
Derivative warrant liability	0	2,815
Note payable — less current portion (Note 9)	33,084	0
Capital lease obligations — less current portion	274	582
Other non-current liabilities	2,162	834
COMMITMENTS AND CONTINGENCIES (Note 10)
STOCKHOLDERS’ EQUITY:
Additional paid-in capital	330,781	299,376
Accumulated deficit	(377,074)	(343,900)
Accumulated other comprehensive loss	(1,272)	(1,148)
TOTAL STOCKHOLDERS’ EQUITY	25,586	26,320
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	70,229	70,484
Preferred Stock
STOCKHOLDERS’ EQUITY:
Preferred stock
Series A convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	19,227	19,227
Series B convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	49,568	49,568
Common Stock
STOCKHOLDERS’ EQUITY:
Common stock, $.01 par value — 150,000,000 shares authorized, 64,862,904 shares issued and outstanding at December 31, 2016 and 100,000,000 shares authorized 45,005,833 shares issued and outstanding at December 31, 2015	649	450
Common stock warrants	$ 3,707	$ 2,747

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	100,000,000
Common stock, shares issued	64,862,904	45,005,833
Common stock, shares outstanding	64,862,904	45,005,833
Series A convertible preferred stock
Preferred stock, shares authorized	1,300,000	1,300,000
Preferred stock, shares issued	600,000	600,000
Preferred stock, shares outstanding	600,000	600,000
Preferred stock, liquidation preference	$ 24,000,000	$ 24,000,000
Series B convertible preferred stock
Preferred stock, shares authorized	8,417	8,417
Preferred stock, shares issued	8,416.251	8,416.251
Preferred stock, shares outstanding	8,416.251	8,416.251
Preferred stock, liquidation preference	$ 50,750,000	$ 50,750,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
NET REVENUE	$ 34,333	$ 22,438
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(2,344)	(1,762)
GROSS PROFIT	31,989	20,676
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	12,375	14,840
GENERAL AND ADMINISTRATIVE EXPENSES	15,263	14,190
SALES AND MARKETING EXPENSES	29,431	28,090
DEPRECIATION AND AMORTIZATION	2,767	2,555
OPERATING EXPENSES	59,836	59,675
NET LOSS FROM OPERATIONS	(27,847)	(38,999)
INTEREST EXPENSE AND OTHER	(5,178)	(4,693)
UNREALIZED FOREIGN CURRENCY LOSS, NET	(40)	(106)
LOSS ON EARLY EXTINGUISHMENT OF DEBT	(2,564)	0
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	2,627	13,283
NET LOSS BEFORE TAXES	(33,002)	(30,515)
PROVISION FOR TAXES	(172)	(130)
NET LOSS	$ (33,174)	$ (30,645)
NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS — Basic and diluted (in dollars per share)	$ (0.63)	$ (0.69)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted (in shares)	52,801,603	44,450,216

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (33,174)	$ (30,645)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(124)	(336)
TOTAL OTHER COMPREHENSIVE LOSS	(124)	(336)
COMPREHENSIVE LOSS	$ (33,298)	$ (30,981)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Total	Common Stock Issued	Common Stock	Common StockCommon Stock Issued	Preferred StockSeries A Convertible Preferred Stock	Preferred StockSeries B Convertible Preferred Stock	Additional Paid-In Capital	Additional Paid-In CapitalCommon Stock Issued	Common Stock Warrants	Accumulated Deficit	Accumulated Other Comprehensive Loss
BALANCE at Dec. 31, 2014	$ 49,519		$ 443		$ 19,227	$ 49,568	$ 292,851		$ 1,497	$ (313,255)	$ (812)
BALANCE (in shares) at Dec. 31, 2014			44,320,342		600,000	8,416.251
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs		$ 924		$ 4				$ 920
Issuance of stock, net of issuance costs (in shares)				341,239
Exercise of stock options	$ 571		$ 3				568
Exercise of stock options (in shares)	344,252		344,252
Modification of common stock warrants	$ 1,250								1,250
Stock-based compensation	5,037						5,037
Net loss	(30,645)									(30,645)
Foreign currency translation adjustments	(336)										(336)
BALANCE at Dec. 31, 2015	26,320		$ 450		$ 19,227	$ 49,568	299,376		2,747	(343,900)	(1,148)
BALANCE (in shares) at Dec. 31, 2015			45,005,833		600,000	8,416
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock, net of issuance costs		$ 26,422		$ 197				$ 26,225
Issuance of stock, net of issuance costs (in shares)				19,645,539
Exercise of stock options	$ 293		$ 2				291
Exercise of stock options (in shares)	285,231		211,532
Modification of common stock warrants	$ 590								590
Issuance of common stock warrants	370								370
Stock-based compensation	4,889						4,889
Net loss	(33,174)									(33,174)
Foreign currency translation adjustments	(124)										(124)
BALANCE at Dec. 31, 2016	$ 25,586		$ 649		$ 19,227	$ 49,568	$ 330,781		$ 3,707	$ (377,074)	$ (1,272)
BALANCE (in shares) at Dec. 31, 2016			64,862,904		600,000	8,416

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (33,174)	$ (30,645)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,767	2,555
Inventory reserve	104	445
Unrealized foreign currency transaction loss	40	106
Amortization of debt discount	1,038	836
Deferred taxes (benefit)	(213)	(223)
Loss on early extinguishment of debt	2,564	0
Stock compensation expense	4,889	5,037
Change in fair value of derivative warrant liability	(2,627)	(13,283)
Changes in assets and liabilities:
Accounts receivable	(4,096)	(8,919)
Prepaid expenses and other current assets	556	405
Inventory	1,000	(386)
Accounts payable	1,073	(487)
Accrued expenses and other current liabilities	1,035	(1,401)
Other long-term liabilities	(55)	596
Net cash used in operating activities	(25,099)	(45,364)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(186)	(451)
Net cash used in investing activities	(186)	(451)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	292	571
Proceeds from sale of common stock	27,763	1,002
Payment of issuance cost of common stock	(1,341)	(27)
Payment of Series B convertible preferred stock offering costs	0	(327)
Payment of debt issuance costs (Note 9)	(1,069)	(264)
Payments on capital lease obligations	(227)	(293)
Changes in restricted cash	6	(37)
Net cash provided by financing activities	25,424	625
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	(235)	(432)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(96)	(45,622)
CASH AND CASH EQUIVALENTS — Beginning of year	31,075	76,697
CASH AND CASH EQUIVALENTS — End of year	30,979	31,075
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	3,958	4,177
Cash paid for income taxes	193	263
Supplemental schedule of noncash investing and financing activities:
Property and equipment acquired under capital leases	76	1,098
Note payable end of term payment accrued but unpaid	1,400	1,050
Common Stock
Supplemental schedule of noncash investing and financing activities:
Common Stock offering costs accrued but unpaid	$ 0	$ 52

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS Alimera Sciences, Inc., together with its wholly-owned subsidiaries, (the Company) is a pharmaceutical company that specializes in the commercialization, research and development of ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company’s only commercial product is ILUVIEN ® , which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in Europe, the Company committed to conduct a five -year, post-authorization, open label registry study in 800 patients treated with ILUVIEN. In the fourth quarter of 2016, the Company requested approval to modify its protocol to cap enrollment in the study due to its post market safety surveillance not showing any unexpected safety signals. Although the Company has not received formal regulatory approval, the Medicines & Healthcare products Regulatory Agency (MHRA) has agreed to allow the Company to suspend enrollment, pending approval of the Company’s protocol amendment. As of December 31, 2016, 548 patients were enrolled in this study. The Company launched ILUVIEN in Germany and the United Kingdom in the second quarter of 2013 and in the U.S. and Portugal in the first quarter of 2015. In addition, the Company has entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in numerous countries in the Middle East, Italy, Australia, New Zealand and Canada.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates in Financial Statements — The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ from those estimates. Principles of Consolidation — The consolidated financial statements include the accounts of Alimera Sciences, Inc. and all wholly-owned subsidiaries. All significant inter-company balances have been eliminated in consolidation. Cash, Cash Equivalents and Restricted Cash — Cash and cash equivalents include cash and highly liquid investments that are readily convertible into cash and have a maturity of 90 days or less when purchased. Generally, cash and cash equivalents held at financial institutions are in excess of federally insured limits. The Company limits its exposure to credit loss by placing its cash and cash equivalents in highly liquid investments with high quality financial institutions. Cash and cash equivalents were $30,979,000 and $31,075,000 as of December 31, 2016 and 2015, respectively, with approximately 92.0% and 90.0% of these balances, respectively held in U.S. based financial institutions. In addition, the Company has certain credit arrangements that require the Company to maintain minimum balances in specific bank accounts as collateral which are recorded as restricted cash. Revenue Recognition — The Company recognizes revenue from its product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. Title passes generally upon shipment or upon receipt by the customer depending on the agreement with the customer. Precise information regarding the receipt of product by the customer is not always readily available. In these cases, the Company estimates the date of receipt based upon shipping policies by geographic location. The Company ’ s shipping policies require delivery within 24 hours of shipment in most instances. Taxes that are collected from customers and remitted to governmental authorities are not included in revenue. In the U.S., the Company sells ILUVIEN to a limited number of pharmaceutical distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the pharmaceutical distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees and other sales-related deductions. Calculating these provisions involves management’s estimates and judgments. The Company reviews its estimates of rebates, chargebacks and other applicable provisions each period and records any necessary adjustments in the current period’s net product sales. The Company estimates reductions to product sales for Medicaid and Veterans’ Administration (VA) programs and for certain other qualifying federal and state government programs. Based upon the Company’s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company’s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received and invoices received for claims from prior quarters that have not been paid. The Company’s reserves related to discounted pricing to VA, Public Health Services and other institutions (collectively qualified healthcare providers) represent the Company’s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., pharmaceutical distributors). The Company’s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company’s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the historical chargebacks that customers have already claimed. The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. The Company will accept returns for three months prior to and up to nine months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company’s products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company’s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are generated through sales primarily to pharmacies, hospitals and wholesalers which began in 2013. The Company does not require collateral from its customers for accounts receivable. The carrying amount of accounts receivable is reduced by an allowance for doubtful accounts that reflects management ’ s best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, management considers many factors in estimating its general allowance, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, management may adjust its assumptions for anticipated changes in any of those or other factors expected to affect collectability. Provisions for doubtful accounts are charged to operations at the time management determines these accounts may become uncollectable. The Company writes off accounts receivable when management determines they are uncollectable and credits payments subsequently received on such receivables to bad debt expense in the period received. The following summarizes activity related to the Company ’ s allowance for doubtful accounts: Years Ended December 31, 2016 2015 (in thousands) Beginning balance $ 118 $ — Bad debt expense — 118 Recovery of bad debt reserve (118 ) — Ending balance $ — $ 118 Inventory — Inventories are stated at the lower of cost or market with cost determined under the first in, first out (FIFO) method. Included in inventory costs are component parts, work-in-progress and finished goods. The Company relies on third party manufacturers for the production of all inventory and does not capitalize any internal costs. The Company periodically reviews inventories for excess, obsolete or expiring inventory and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated, or if there are any further determinations that inventory will not be marketable based on estimates of demand, additional inventory write-downs will be required. Intangible Assets — The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, which approximates a straight-line basis, over the estimated periods benefited. The estimated useful life of the intangible asset is approximately thirteen years . Property and Equipment — Property and equipment are stated at cost. Additions and improvements are capitalized while repairs and maintenance are expensed. Depreciation is provided on the straight-line method over the useful life of the related assets beginning when the asset is placed in service. The estimated useful lives of the individual assets are as follows: furniture, fixtures and manufacturing equipment, five years ; automobiles, four years ; office equipment and leasehold improvements, 29 months to five years ; and software, three years . Impairment — Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, the Company evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved. Income Taxes — In accordance with the Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 740, Income Taxes , the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position; therefore, no ASC 740-10 liabilities for uncertain tax positions have been recorded. The Company will recognize accrued interest and penalties related to unrecognized tax benefits, if any, as interest expense and income tax expense, respectively, in the consolidated statements of operations. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets as a result of the Company ’ s history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations. Research and Development Costs — Research and development costs are expensed as incurred. Research and development expenses were $2,146,000 and $2,395,000 for the years ended December 31, 2016 and 2015, respectively. Stock-Based Compensation — The Company has stock option plans which provide for grants of stock options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair market values of such stock at the dates of grant. Compensation cost is recognized for all share-based awards based on the grant date fair value in accordance with the provisions of ASC 718, Compensation — Stock Compensation . The fair values for the options are estimated at the dates of grant using a Black-Scholes option-pricing model. Additionally, the Company sponsors an employee stock purchase plan (ESPP) under which employees may elect payroll withholdings to fund purchases of the Company’s stock at a discount. The Company estimates the fair value of the option to purchase shares of the Company’s common stock using the Black-Scholes valuation model and recognizes compensation expense in accordance with the provisions of ASC 718-50, Employee Share Purchase Plans . Derivative Financial Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase Series A Convertible Preferred Stock or common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants were considered derivative instruments at issuance because the agreements provide for settlement in Series A Convertible Preferred Shares or common shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The warrant exercise price no longer can be adjusted at some point in the future. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of change in fair value of derivative warrant liability in the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. As of December 31, 2016 and 2015, these warrants represented the only outstanding derivative instruments issued or held by the Company. Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and current assets and liabilities approximate their fair value because of their short maturities. The weighted average interest rate of the Company’s notes payable approximates the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the note approximates the fair value. The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Translation Policy - The U.S. dollar is the functional currency for Alimera Sciences, Inc. The Euro is the functional currency for the majority of the Company ’ s subsidiaries operating outside of the U.S. For Alimera Sciences, Inc., foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for non-monetary balance sheet accounts, which are remeasured at historical exchange rates. Revenue and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the non-monetary balance sheet amounts, which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurements are included in the statement of operations. The financial statements of the foreign subsidiaries whose functional currency is not the U.S. dollar, have been translated into U.S. dollars in accordance with ASC 830-30, Translation of Financial Statements . For the subsidiaries operating outside of the U.S. that are denominated in the Euro, assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive loss. Earnings Per Share (EPS) — Basic EPS is calculated in accordance with ASC 260, Earnings per Share by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants, convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Years Ended December 31, 2016 2015 Series A convertible preferred stock 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 8,416,251 Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 1,795,663 738,331 Stock options 10,804,412 9,475,890 Total 34,550,161 32,164,307 Reporting Segments — The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, U.S. and International. Promotional and Advertising Costs — Promotional and advertising costs are expensed as incurred. Adoption of New Accounting Standards — In June 2014, the FASB issued Accounting Standards Update (ASU) 2014-12, Compensation Stock - Compensation (Topic 718) . ASU 2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. It requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and follows existing accounting guidance for the treatment of performance conditions. The standard was effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The adoption of this guidance did not have a material impact on its financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on its financial statements. In April 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company elected to early adopt ASU 2015-03 effective December 31, 2015, and as a result the Company reclassified $629,000 from deferred financing costs to note payable in its Consolidated Balance Sheet as of December 31, 2015. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes , which simplifies the presentation of deferred income taxes. This ASU requires that deferred tax assets and liabilities be classified as non-current in a statement of financial position. The Company elected to early adopt ASU 2015-17 effective December 31, 2015 on a prospective basis. Adoption of this ASU resulted in a reclassification of our net current deferred tax asset to the net non-current deferred tax asset in its Consolidated Balance Sheet as of December 31, 2015. Accounting Standards Issued but Not Yet Effective — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) , as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company ’ s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company’s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory . This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The Company does not expect the impact of the adoption to have a material effect on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718) . This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The Company does not expect the impact of the adoption to have a material effect on its financial statements.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	GOING CONCERN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. To date the Company has incurred recurring losses, negative cash flow from operations and has accumulated a deficit of $377,074,000 from the Company’s inception through December 31, 2016 . As of December 31, 2016 , the Company had approximately $30,979,000 in cash and cash equivalents. The Company's ability to achieve profitability and positive cash flow is dependent upon its ability to increase revenue and contain its expenses. Further, the Company must maintain compliance with the debt covenants of its debt agreement (see Note 9). In 2016, in order to continue to fund its operations and meet its debt covenants, the Company raised additional equity and amended its debt agreement. In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months. In order to meet the Company’s working capital needs through the next twelve months and maintain compliance with its debt covenants, the Company may need to raise additional debt or equity financing. The Company may be able to access capital under the Company’s current at-the-market offering facility, which has approximately $22,000,000 of remaining availability. The Company implemented a cost savings program in late 2016 that the Company believes will help decrease our cash burn over the next twelve months. While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has a plan in place to reduce spending in order to satisfy its obligations due within one year from the date of issuance of these financial statements, there can be no guarantees on the Company’s ability to maintain debt compliance, raise additional equity, or successfully implement its cost reduction plans. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventory consisted of the following: December 31, 2016 2015 (In thousands) Component parts (1) $ 115 $ 131 Work-in-process (2) 18 333 Finished goods 353 1,525 Total inventory 486 1,989 Inventory reserve (40 ) (437 ) Inventory — net $ 446 $ 1,552 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EEA regulatory authorities.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT Property and equipment consisted of the following: December 31, 2016 2015 (In thousands) Furniture and fixtures $ 391 $ 376 Office equipment 838 794 Automobiles 762 1,028 Software 973 902 Leasehold improvements 460 439 Manufacturing equipment 997 970 Total property and equipment 4,421 4,509 Less accumulated depreciation and amortization (2,634 ) (1,956 ) Property and equipment — net $ 1,787 $ 2,553 Depreciation and amortization expense associated with property and equipment totaled $822,000 and $614,000 for the years ended December 31, 2016 and 2015 , respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS As a result of the U.S. Food and Drug Administration ’ s (FDA) approval of ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of $25,000,000 (the pSivida Milestone Payment) in October 2014 (see Note 8). The gross carrying amount of the intangible asset is $25,000,000 , which is being amortized over approximately 13 years from the acquisition date. The net book value of the intangible asset was $20,604,000 and $22,549,000 as of December 31, 2016 and 2015, respectively, and amortization expense was $1,946,000 and $1,940,000 for the years ended December 31, 2016 and 2015, respectively. The estimated remaining amortization as of December 31, 2016 is as follows (in thousands): Years Ending December 31 2017 $ 1,940 2018 1,940 2019 1,940 2020 1,946 2021 1,940 Thereafter 10,898 Total $ 20,604

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
ACCRUED EXPENSES	ACCRUED EXPENSES Accrued expenses consisted of the following: December 31, 2016 2015 (In thousands) Accrued clinical investigator expenses $ 1,122 $ 732 Accrued other compensation expenses 1,020 804 Accrued rebate, chargeback and other revenue reserves 809 452 Accrued End of Term Payment (Note 9) — 1,050 Other accrued expenses 807 873 Total accrued expenses $ 3,758 $ 3,911

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LICENSE AGREEMENTS	LICENSE AGREEMENTS The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device in February 2005 with a subsequent amendment in 2008. pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. The agreement with pSivida provides the Company with a worldwide exclusive license to develop and sell ILUVIEN. The Company’s license rights to pSivida’s proprietary delivery device could revert to pSivida if the Company were to (i) fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of its agreement with pSivida within 30 days after notice of such breaches or such longer period (up to 90 days ) as may be reasonably necessary if the breach cannot be cured within such 30 -day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days ; or (iv) notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida’s proprietary delivery device. The Company was not in breach of its agreement with pSivida as of December 31, 2016. The Company must share 20% of net profits, determined on a cash basis and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida’s share of net profits, which is recovered as a reduction of future royalty payments. As of December 31, 2016 and 2015 , the Company could offset future royalty payments to pSivida in the amounts of $25,828,000 and $21,565,000 , respectively, due to the accumulation of commercialization costs. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying consolidated financial statements. As a result of the FDA’s approval of ILUVIEN in September 2014, the Company paid pSivida a milestone payment of $25,000,000 in October 2014. As of December 31, 2016 the Company owed pSivida approximately $240,000 for their portion of net profits on a cash basis, as defined in the amended and restated agreement, from the fourth quarter of 2016. In the second quarter of 2016, pSivida disputed portions of the Company’s claimed commercialization costs for the year ended December 31, 2014. As part of this dispute, pSivida notified the Company that it disagreed with $1,290,000 of the $12,956,000 in commercialization costs receivable that the Company had reported as of December 31, 2014 and claimed incremental profit sharing payments of $136,000 for the year ended December 31, 2014. The Company is disputing pSivida’s assertions using the alternative dispute resolution mechanism under the pSivida Agreement. If pSivida’s assertions were to prevail in the alternative dispute resolution mechanism and their assertions were then applied to the commercialization cost calculations for the years ended December 31, 2016 and 2015, then the Company believes the commercialization costs receivable from pSivida would be reduced from $25,828,000 to $21,201,000 as of December 31, 2016 and from $21,565,000 to $18,504,000 as of December 31, 2015 and the impact on the statements of operations for the years ended December 31, 2016 and 2015 would be immaterial.

Loan Agreements

Loan Agreements	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
LOAN AGREEMENTS	LOAN AGREEMENTS Hercules Loan Agreement 2014 Loan Agreement In April 2014, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2014 Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to $35,000,000 (2014 Term Loan), which Limited and Hercules amended in November 2015 (the First Loan Amendment), March 2016 (the Second Loan Amendment), May 2016 (the Third Loan Amendment) and October 2016 (the Fourth Loan Amendment and, collectively with the 2014 Loan Agreement, the First Loan Amendment, the Second Loan Amendment and the Third Loan Amendment, the Term Loan Agreement). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of $10,000,000 to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay a 2013 term loan with Silicon Valley Bank. Hercules made an additional advance of $25,000,000 to Limited in September 2014, following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Loan Agreement provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrued at a floating per annum rate equal to the greater of (i) 10.90% , or (ii) the sum of (A) 7.65% , plus (B) the prime rate. Following the interest only period the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. The interest rate on the Term Loan Agreement was 11.25% as of December 31, 2016. First Loan Amendment In November 2015, Limited and Hercules amended the 2014 Loan Agreement to extend the interest only payments through May 2017. In connection with the First Loan Amendment, Limited paid to Hercules an amendment fee of $262,500 and agreed to make an additional payment of $1,050,000 , equal to 3% of the 2014 Term Loan at the time of the final payment (End of Term Payment). Limited and the Company, on a consolidated basis with the Company’s other subsidiaries (the Consolidated Group), agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the Term Loan Agreement and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement. In connection with the First Loan Amendment, Limited agreed to covenants regarding certain revenue thresholds and a liquidity threshold. Second Loan Amendment In January 2016, the revenue threshold covenant was not met by the Consolidated Group and as a result, in March 2016, Limited and Hercules entered into the Second Loan Amendment, which further amended certain terms of the 2014 Loan Agreement. In conjunction with the Second Loan Amendment, Hercules waived this covenant violation. The Second Loan Amendment adjusted the revenue covenant to a rolling three-month calculation, first measured for the three months ended May 31, 2016. In addition, the Second Loan Amendment increased the liquidity covenant. Upon execution of the Second Loan Amendment, Limited paid Hercules an amendment fee of $350,000 and agreed to increase the End of Term Payment to $1,400,000 from $1,050,000 , which is payable in May 2018. The Company concluded that the Second Loan Amendment resulted in a substantial modification of the terms of debt when considered with the First Loan Amendment in accordance with the guidance in ASC 470-50, Debt . As a result, the Company accounted for the Second Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately $2,564,000 within the consolidated statement of operations for the year ended December 31, 2016. The loss on early extinguishment consisted primarily of the unamortized debt discount associated with the warrant and debt issuance costs incurred prior to the Second Loan Amendment, the incremental fair value of the warrant as a result of modifying the terms of the warrant and the debt issuance costs of $360,000 paid to Hercules for the Second Loan Amendment. Third Loan Amendment and July 2016 Waiver In May 2016, Limited and Hercules entered into the Third Loan Amendment to expand the definition of liquidity to allow for the inclusion of cash of up to $2,000,000 in bank accounts outside of the U.S. and the United Kingdom. In July 2016, Limited obtained a waiver of the requirements of the liquidity covenant (the Waiver) because the Consolidated Group was not in compliance with the liquidity covenant as of June 30, 2016. The Waiver cured the default of the liquidity covenant then existing under the Term Loan Agreement and decreased the liquidity requirement. In addition, the Waiver modified the three-month revenue covenant so that it was not measured at July 31, 2016 and reduced the three-month revenue target to be measured at August 31, 2016. Following execution of the Waiver, Limited incurred a weekly ticking fee equal to 0.05% multiplied by the outstanding principal amount through the closing of the Company’s public offering in August 2016 (see Note 12 Common Stock), totaling $65,000 . Further, Limited paid Hercules a fee of $350,000 associated with the Waiver. Fourth Loan Amendment In October 2016, Limited entered into the Fourth Loan Amendment with Hercules, which further amended certain terms of the Term Loan Agreement. Pursuant to the terms of the Fourth Loan Amendment, Hercules agreed to provide up to an additional $10,000,000 to Limited with (i) the first $5,000,000 available at Limited’s option through June 30, 2017 subject to (A) the Consolidated Group’s achievement of $12,000,000 in trailing three month net product revenue and (B) no event of default having occurred since October 20, 2016 (the Effective Date) and (ii) the second $5,000,000 available at Limited’s option through December 31, 2017 subject to (A) the Consolidated Group’s achievement of $15,000,000 in trailing three month net product revenue, (B) no event of default having occurred since the Effective Date and (C) the prior $5,000,000 having been advanced to Limited (the Additional Advances and, together with the 2014 Term Loan, the Term Loan). The Fourth Loan Amendment provides for interest only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Term Loan accrues at a floating per annum rate equal the greater of (i) 11.0% and (ii) the sum of (A) 11.0% plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus 3.5% . In addition to the interest described above, the principal balance of the Term Loan will bear “payment-in kind” interest at the rate of 1.0% (PIK Interest), which PIK Interest will be added to the outstanding principal balance of the Term Loan so as to increase the outstanding principal balance of the Term Loan on each payment date for the Term Loan and which amount will be payable when the aggregate outstanding principal amount of the Term Loan is payable. The Term Loan will be due and payable to Hercules in 24 equal monthly payments of principal and interest following the Interest-Only Period beginning on December 1, 2018 and matures in full on November 1, 2020. Limited paid Hercules a facility charge of $337,500 and reimbursed Hercules for legal and diligence fees incurred in connection with the Fourth Loan Amendment. If Limited prepays the Term Loan, it will pay Hercules a prepayment penalty (i) if such amounts are prepaid in any of the first 12 months following the Effective Date, equal to 3.0% of the principal amount of the Term Loan being repaid, (ii) if such amounts are prepaid after 12 months but prior to 24 months following the Effective Date, equal to 2.0% of the principal amount of the Term Loan being repaid, and (iii) if such amounts are prepaid at any time thereafter, equal to 1.0% of the principal amount of the Term Loan being repaid. The Consolidated Group also agreed to customary affirmative and negative covenants, including, without limitation, covenants relating to minimum liquidity, minimum trailing six-month net revenue and adjusted EBITDA and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the Term Loan Agreement, as amended by the Fourth Loan Amendment and an increase to the applicable interest rate and would permit Hercules to exercise remedies with respect to the collateral under the Term Loan Agreement, as amended by the Fourth Loan Amendment. In the event that the Company maintains $35,000,000 in liquidity, including cash and eligible accounts receivable, at the end of the month and has not been and is not in breach of the amended debt facility, the six-month trailing revenue covenant is waived for such month. As of December 31, 2016, the Company’s liquidity as defined under the Term Loan Agreement was $40,923,000 , which consisted of $30,979,000 in cash and cash equivalents and 80% of the Company’s $12,430,000 U.S. eligible accounts receivable. General Discussion of the Term Loan Agreement Pursuant to the Term Loan Agreement, Limited’s obligations to Hercules are secured by a first-priority security interest in substantially all of Limited’s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited’s intellectual property requiring Hercules’ consent prior to the sale of such intellectual property. The Company and certain of the Company’s other subsidiaries are guarantors of the obligations of Limited to Hercules under the Term Loan Agreement pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first-priority security interest in substantially all of their respective assets excluding intellectual property. The Term Loan Agreement also places limitations on the Company’s ability to declare or pay any dividend or distribution on any shares of capital stock. 2014 Warrant In connection with Limited entering into the 2014 Loan Agreement, the Company issued a warrant to Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share (the 2014 Warrant). Sixty percent of the 2014 Warrant was exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014. The Company agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to 660,377 and decrease the exercise price to $2.65 per share. Upon entering into the Second Loan Amendment, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 862,069 and decrease the exercise price to $2.03 per share. In connection with the July 2016 Waiver, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 1,258,993 and decrease the exercise price to $1.39 per share. 2016 Warrant In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to 458,716 shares of the Company’s common stock at an exercise price of $1.09 per share, which was equal to $500,000 divided by the lowest volume-weighted average sale price for a share of the Company’s common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant). Fair Value of Debt The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing and the fair value of the warrants that were issued in connection with the Company’s notes payable are immaterial. Therefore, the carrying amount of the notes approximated their fair value at December 31, 2016 and 2015.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Term Note Payable — The Company entered into the Term Loan Agreement in April 2014 and amended the agreement in November 2015, March 2016, May 2016 and October 2016 (Note 9). As of December 31, 2016 a schedule of future minimum principal payments, excluding PIK Interest and excluding the End of Term Payment of $1,400,000 which is payable in May 2018, under the Note Payable is as follows (in thousands): Years Ending December 31 (In thousands) 2017 $ — 2018 $ 1,300 2019 $ 16,526 2020 $ 17,174 Total $ 35,000 As of December 31, 2016 and 2015 , the Company had $336,000 and $333,000 accrued and unpaid interest payable on the Notes Payable, respectively. In addition, the Company is required to make an additional payment of $1,400,000 in May 2018. Operating Leases — The Company leases office space and equipment under non-cancelable agreements accounted for as operating leases. The leases generally require that the Company pay taxes, maintenance, and insurance. Management expects that in the normal course of business, leases that expire will be renewed or replaced by other leases. In August 2014, the Company signed a lease for office space in the U.S. through September 2021. In December 2014, Limited signed a lease for office space in the United Kingdom through December 24, 2024, however the lease is cancellable after December 17, 2019. The lease has a contingent escalation clause based on inflation beginning in 2020. The Company also leases office space in Germany and Portugal that expire in July 2018 and March 2020, respectively. The Company also leases office space in France, consisting of less than 1,000 square feet. As part of the Company's decision in 2016 to close operations in France, which will not be completed until early 2017, the Company gave notice to the leasing company that the Company would not be renewing the lease after April 2017. As of December 31, 2016 , a schedule by year of future minimum payments under all of the Company’s operating leases is as follows: Years Ending December 31 (In thousands) 2017 $ 547 2018 512 2019 459 2020 350 2021 268 Total $ 2,136 Rent expense under all operating leases totaled approximately $544,000 and $541,000 for the years ended December 31, 2016 and 2015 , respectively. Capital Leases — The Company leases equipment under capital leases. The property and equipment is capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. As of December 31, 2016 , a schedule by year of future minimum payments under capital leases, together with the present value of minimum lease payments, is as follows (in thousands): Years Ending December 31 (In thousands) 2017 $ 300 2018 289 2019 107 2020 3 Total 699 Less amount representing interest (41 ) Less amount representing executory costs (193 ) Present value of minimum lease payments 465 Less current portion (191 ) Non-current portion $ 274 Property and equipment under capital leases, which are included in property and equipment (Note 5), consisted of the following: December 31, 2016 2015 (In thousands) Automobiles $ 762 $ 1,028 Office equipment 63 63 Less accumulated depreciation (342 ) (212 ) Total $ 483 $ 879 Depreciation expense associated with property and equipment under capital leases was approximately $267,000 and $210,000 for the years ended December 31, 2016 and 2015 , respectively. Significant Agreements — In February 2010, the Company entered into an agreement with a third party manufacturer for the manufacture of the ILUVIEN implant, the assembly of the ILUVIEN applicator and packaging of the completed ILUVIEN commercial product. The Company is responsible for supplying the ILUVIEN applicator and the active pharmaceutical ingredient. In accordance with the terms of the agreement, the Company must order at least 80% of the ILUVIEN units required in the U.S., Canada and the EEA from the third party manufacturer for an initial term of six years. The agreement has an initial six year term and will automatically renew for successive one year periods unless either party delivers written notice of non-renewal to the other at least 12 months prior to the end of the then current term. In February 2016, the Company amended and restated its agreement to extend the term to five years, at which point it will automatically renew for successive one year periods unless either party delivers notice of non-renewal to the other party at least 12 months prior to the end of the term or any renewal term. In May 2013, the Company entered into an agreement with the first of three contract research organizations (CROs) for clinical and data management services to be performed in connection with the five -year, post-authorization, open label registry study in 800 patients treated with ILUVIEN per the labeled indication in the EEA. Since May of 2013 nine additional agreements have been entered into for work with these CROs. For the years ended December 31, 2016 and 2015 , the Company incurred $157,000 and $591,000 , respectively, of expense associated with these agreements. As of December 31, 2016 and 2015, $76,000 and $150,000 , respectively, is included in accrued expenses (Note 7). As of December 31, 2016, the Company expects to incur an additional $587,000 of expense associated with these agreements through December 31, 2019. In November 2012, the Company entered into a master services agreement with Quintiles Commercial Europe Limited. Under the agreement, Quintiles Commercial Europe Limited and its affiliates (collectively, Quintiles Commercial) provided certain services to us in relation to the commercialization of ILUVIEN, in France, Germany and the United Kingdom. In December 2013 and January 2014, respectively, the Company transitioned our German and United Kingdom country manager positions in-house. In April 2015, the Company terminated the project orders associated with France and Germany and transitioned the persons employed by Quintiles Commercial to our payroll. In July 2015, the Company terminated the remaining project orders associated with the United Kingdom and transitioned the persons employed by Quintiles Commercial to the Company ’ s payroll. For the year ended December 31, 2015, the Company incurred $1,030,000 of expense associated with this agreement. As of December 31, 2016 and 2015, $164,000 and $170,000 , respectively, was included in accrued expenses. As of December 31, 2015 the master services agreement with Quintiles Commercial had been terminated and no expense was incurred during the year ended December 31, 2016. Employment Agreements — The Company is party to employment agreements with five executives. The agreements generally provide for annual salaries, bonuses, and benefits and for the “at-will” employment of such executives. Effective January 1, 2016, the Company is party to five agreements with salaries ranging from $253,000 to $519,000 . If any of the agreements are terminated by the Company without cause, or by the employee for good reason, as defined in the agreements, the Company will be liable for one year of salary and benefits. Certain other employees have general employment contracts which include stipulations regarding confidentiality, Company property, severance in an event of change of control and miscellaneous items.

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
PREFERRED STOCK	PREFERRED STOCK Series A Convertible Preferred Stock On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000 , prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by $2.66 (Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s NDA for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000 . The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company ’ s ability to declare or pay any dividend or distribution on any shares of capital stock. Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants was subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore, the warrants were recorded as a liability at issuance. These adjustment features lapsed in September 2014. As of December 31, 2016 and 2015 the fair market value of the warrants was estimated to be $188,000 and $2,815,000 , respectively. The Company recorded gains of $2,627,000 and $13,283,000 as a result of the change in fair value of the warrants during the years ended December 31, 2016 and 2015, respectively. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor. Series B Convertible Preferred Stock On December 12, 2014, the Company closed a preferred stock financing in which it sold 8,291.873 shares of Series B Convertible Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of $50,000,000 , prior to the payment of approximately $432,000 of related issuance costs. The Company has also agreed to issue the purchasers an additional 124.378 shares of Series B Convertible Preferred Stock as a subscription premium. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company’s existing Series A Convertible Preferred Stock, and senior to the Company’s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock will not have voting rights. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. The Company determined that the conversion option of the Preferred Shares represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of $750,000 during the year ended December 31, 2014 as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.

Stock Incentive Plans

Stock Incentive Plans	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK INCENTIVE PLANS	STOCK INCENTIVE PLANS The Company has stock option and stock incentive plans which provide for grants of shares to employees and grants of options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair values of such stock at the dates of grant. Options granted to employees typically become exercisable over a four -year vesting period and have a ten -year contractual term. Initial options granted to directors typically vest over a four -year period and have a ten -year contractual term. Annual option grants to directors typically vest immediately and have a ten -year contractual term. Upon the exercise of stock options, the Company may issue the required shares out of authorized but unissued common stock or out of treasury stock at management’s discretion. A summary of stock option transactions under the plans are as follows: Years Ended December 31, 2016 2015 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 9,475,890 $ 3.43 7,681,256 $ 3.03 Grants 2,195,250 2.05 2,570,000 4.62 Forfeitures (581,497 ) 3.15 (431,114 ) 4.79 Exercises (285,231 ) 1.41 (344,252 ) 1.66 Options outstanding at year end 10,804,412 3.22 9,475,890 3.43 Options exercisable at year end 7,363,400 3.29 5,808,528 3.27 Weighted average per share fair value of options granted during the year $ 1.55 $ 3.58 The following table provides additional information related to outstanding stock options, fully vested stock options, and stock options expected to vest as of December 31, 2016 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 10,804,412 $ 3.22 6.45 years $ — Exercisable 7,363,400 3.29 5.42 years — Outstanding, vested and expected to vest 10,374,846 3.23 6.35 years — The Company estimated the fair value of options granted using the Black-Scholes option pricing model. Use of a valuation model requires the Company to make certain assumptions with respect to selected model inputs. Changes in these input variables would affect the amount of expense associated with equity-based compensation. Expected volatility is based on the historical volatility of the Company ’ s common shares over the expected term of the stock option grant. To estimate the expected term, the Company utilizes the “simplified” method for “plain vanilla” options as discussed within the Securities and Exchange Commission’s Statement of Accounting Bulletin 107. The Company intends to utilize the simplified method for the foreseeable future until more detailed information about exercise behavior will be more widely available. The risk-free interest rate is based on U.S. Treasury Daily Treasury Yield Curve Rates corresponding to the expected life assumed at the date of grant. Dividend yield is zero as there are no payments of dividends made or expected. The weighted-average assumptions used for option grants were as follows: Years Ended December 31, 2016 2015 Risk-free interest rate 1.57 % 1.55 % Volatility factor 93.54 % 96.80 % Grant date fair value of common stock options $ 1.55 $ 3.58 Weighted-average expected life 5.99 years 6.03 years Assumed forfeiture rate 10.00 % 10.00 % Employee stock-based compensation expense related to stock options recognized in accordance with ASC 718 was as follows: Years Ended December 31, 2016 2015 (In thousands) Sales and marketing $ 1,109 $ 925 Research, development and medical affairs 886 1,271 General and administrative 2,814 2,732 Total employee stock-based compensation expense $ 4,809 $ 4,928 As of December 31, 2016, there was approximately $7,049,000 of total unrecognized compensation cost related to outstanding stock option awards that will be recognized over a weighted average period of 2.35 years. The total fair value of shares vested during the year ended December 31, 2016 was approximately $4,955,000 . The total estimated fair value of options granted during the years ended December 31, 2016 and 2015 was $3,410,000 and $9,172,000 , respectively. The total estimated intrinsic value of options exercised during the years ended December 31, 2016 and 2015 was $65,000 and $568,000 , respectively. As of December 31, 2016, the Company was authorized to grant options to purchase up to an additional 668,830 shares under the 2010 Equity Incentive Plan. The Company’s 2010 Plan provides for annual increases in the number of shares available for issuance thereunder on the first day of each fiscal year equal to the lesser of: (1) 2,000,000 shares of our common stock; (2) 4% of the shares of common stock outstanding at that time; and (3) such other amount as our board of directors may determine. On January 1, 2017, an additional 2,000,000 shares became available for future issuance under the 2010 Plan. These additional shares from the annual increase under the 2010 Plan are not included in the foregoing discussion.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
COMMON STOCK WARRANTS	COMMON STOCK WARRANTS The Company has issued warrants to purchase common stock to various members of the board of directors, third-parties for services, and lenders. Total warrants to purchase common stock issued and exercisable were 1,795,663 and 738,331 as of December 31, 2016 and 2015 , respectively. As of December 31, 2016, the exercise prices ranged from $1.09 to $11.00 per share. The warrants are exercisable for a period between 5 and 10 years from the issuance date. In connection with Limited entering into the 2014 Loan Agreement (Note 9), the Company entered into the 2014 Warrant to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. Sixty percent of the warrants were exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014. The Company agreed to amend the 2014 Warrant in connection with the First Loan Amendment to increase the number of shares issuable upon exercise to 660,377 and decrease the exercise price to $2.65 per share. Upon entering into the Second Loan Amendment, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 862,069 and decrease the exercise price to $2.03 per share. In connection with the July 2016 Waiver, the Company agreed to further amend the 2014 Warrant to increase the number of shares issuable upon exercise to 1,258,993 and decrease the exercise price to $1.39 per share. In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue the 2016 Warrant to purchase up to 458,716 shares of the Company’s common stock at an exercise price of $1.09 per share, which was equal to $500,000 divided by the lowest volume-weighted average sale price for a share of the Company’s common stock reported over any ten consecutive trading days during the period commencing on and including September 23, 2016 and ending on the earlier to occur of (i) December 30, 2016 (inclusive of such date), and (ii) the second trading day immediately preceding the date of closing of a merger event (as defined in the 2016 Warrant).

Concentrations and Credit Risk

Concentrations and Credit Risk	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND CREDIT RISK	CONCENTRATIONS AND CREDIT RISK For the years ended December 31, 2016 and 2015, there were only two customers within the U.S. segment. These two customers, which are large pharmaceutical distributors, accounted for approximately 75% and 68% , respectively, of the Company ’ s total consolidated revenues. These two same customers accounted for approximately 90% and 88% of the Company ’ s consolidated accounts receivable as of December 31, 2016 and 2015, respectively. For the years ended December 31, 2016 and 2015, there were no vendors that comprised more than 10% of the Company ’ s total purchases. The Company relies on a single manufacturer for ILUVIEN, a single manufacturer for the ILUVIEN applicator and a single active pharmaceutical ingredient manufacturer for ILUVIEN’s active pharmaceutical ingredient.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The components of net loss before taxes are as follows: Years Ended December 31, 2016 2015 (In thousands) United States $ (8,516 ) $ (6,026 ) Foreign (24,486 ) (24,489 ) Loss before provision for income taxes $ (33,002 ) $ (30,515 ) In accordance with ASC 740, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against the net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. The provision for income taxes consists of the following components: Years Ended December 31, 2016 2015 (In thousands) Current expense (benefit): Federal $ — $ — State — — Foreign 385 353 Current income tax expense 385 353 Deferred expense (benefit): Federal 3,099 6,509 State (858 ) 819 Foreign (213 ) (223 ) 2,028 7,105 Valuation allowance (2,241 ) (7,328 ) Deferred income tax benefit (213 ) (223 ) Total income tax expense $ 172 $ 130 The following summarizes activity related to the Company ’ s valuation allowance: Years Ended December 31, 2016 2015 (In thousands) Valuation allowance at beginning of period $ (53,727 ) $ (46,399 ) Income tax provision (2,241 ) (7,328 ) Release of valuation allowance — — Other — — Valuation allowance at end of period $ (55,968 ) $ (53,727 ) Worldwide net deferred tax assets and liabilities are as follows: December 31, 2016 2015 Deferred tax assets (In thousands) Depreciation and amortization $ 12 $ 3 Other deferred tax assets 5,824 4,643 NOL carry-forwards 38,183 36,941 Research and development costs 3,063 4,193 Collaboration agreement receivable reserves 9,327 8,186 Valuation allowance (55,968 ) (53,727 ) Total deferred tax assets $ 441 $ 239 Deferred tax liabilities Unrealized foreign currency gains $ — $ (12 ) Other deferred tax liabilities (5 ) (4 ) Total deferred tax liabilities (5 ) (16 ) Net deferred tax assets and deferred tax liabilities $ 436 $ 223 A reconciliation from the federal statutory rate to the total provision for income taxes is as follows: Years Ended December 31, 2016 2015 Amount Percent Amount Percent Federal tax benefit at statutory rate $ (11,219 ) 34.0 % $ (10,375 ) 34.0 % State tax — net of federal benefit (10 ) — (715 ) 2.4 Permanent items and other (225 ) 0.7 (3,997 ) 13.1 Prior period transfer pricing adjustments — — — — Foreign rate differential 8,470 (26.1 ) 8,352 (27.4 ) Deferred rate change 825 (2.5 ) — — Other 90 (0.3 ) (463 ) 1.5 Change in valuation allowance 2,241 (6.3 ) 7,328 (24.0 ) Total tax expense (benefit) $ 172 (0.5 )% $ 130 (0.4 )% The change in permanent differences and other items from 2015 to 2016 is primarily due to the decreased benefit associated with the current period movement of the derivative warranty liability. However, as such current period movement creates an increased net operating loss in the United States which has a full valuation allowance recorded against its deferred tax assets, there is effectively no impact to total tax expense. Also included in the 2016 permanent differences is expense related to incentive stock options of approximately $517,000 . A rollforward of the Company’s uncertain tax positions is as follows: Years Ended December 31, 2016 2015 (In thousands) Balance of uncertain tax positions at beginning of period $ 46 $ — Gross increases - tax positions in current period 16 3 Gross increases - tax positions in prior period 13 43 Gross decreases - tax positions in prior period (16 ) — Settlements — — Lapse of statute of limitations — — Balance of uncertain tax positions at end of period $ 59 $ 46 Included in the balance of unrecognized tax benefits as of December 31, 2016 and December 31, 2015 are approximately $59,000 and $46,000 , respectively, of tax benefits related to research and development tax credits. In accordance with ASC 740-10, such attributes are reduced the amount that is expected to be recognized in the future. The Company does not accrue interest or penalties as there is no risk of additional tax liability due to significant NOLs available. The Company does not expect any decreases to the unrecognized tax benefits within the next twelve months due to any lapses in statute of limitations. Tax years from 2012 to 2015 remain subject to examination in California, Georgia, Kentucky, Tennessee, Texas and on the federal level, with the exception of the assessment of NOL carry-forwards available for utilization which can be examined for all years since 2003. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the entire net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations. As of December 31, 2016 and 2015 , the Company had federal net operating loss (NOL) carry-forwards of approximately $104,944,000 and $100,844,000 and state NOL carry-forwards of approximately $83,270,000 , and $84,301,000 respectively, that are available to reduce future income unless otherwise taxable. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2035 and the state NOL carry-forwards will expire at various dates between 2020 and 2035. NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section 382 (Section 382) (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership, including its Initial Public Offering (IPO), have occurred that would limit the Company’s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Section 382 (or comparable provisions of state law). The Company has determined that a Section 382 change in ownership occurred in late 2015. Therefore, the annual utilization of the Company’s NOLs are subject to certain limitations under Section 382 and other limitations under state tax laws. The Company is currently in the process of calculating these limitations. Any reduction to the Company’s NOL deferred tax asset due to the annual Section 382 limitation and the NOL carryforward period would result in an offsetting reduction in valuation allowance recorded against the NOL deferred tax asset. Therefore, any limitation would not have an impact on the statements of operations for the periods presented. The results of the analysis on the impact to the Company’s NOLs will be disclosed at a later date. As of December 31, 2016, the Company had cumulative book losses in foreign subsidiaries of approximately $92,939,000 . The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company applies ASC 820, Fair Value Measurements in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows: Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. There have been no changes in the methodologies used as of December 31, 2016 and 2015. The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: December 31, 2016 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ — $ — $ — $ — Assets measured at fair value $ — $ — $ — $ — Liabilities: Derivative warrant liability (2) $ — $ 188 $ — $ 188 Liabilities measured at fair value $ — $ 188 $ — $ 188 December 31, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 1,010 $ — $ — $ 1,010 Assets measured at fair value $ 1,010 $ — $ — $ 1,010 Liabilities: Derivative warrant liability (2) $ — $ 2,815 $ — $ 2,815 Liabilities measured at fair value $ — $ 2,815 $ — $ 2,815 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS The Company has a salary deferral 401(k) plan which covers substantially all U.S. employees of the Company. The Company matches participant contributions subject to certain plan limitations. Compensation expense associated with the Company’s matching plan totaled $287,000 and $268,000 for the years ended December 31, 2016 and 2015 , respectively. The Company may also make an annual discretionary profit-sharing contribution. No such discretionary contributions were made during the years ended December 31, 2016 and 2015 , respectively. In April 2010, the Company established an Employee Stock Purchase Plan (the Purchase Plan). Under the Company’s Purchase Plan, eligible employees can participate and purchase common stock semi-annually through accumulated payroll deductions. The Purchase Plan is administered by the Company’s board of directors or a committee appointed by the Company’s board of directors. Under the Purchase Plan eligible employees may purchase stock at 85% of the lower of the fair market value of a share of Common Stock on the offering date or the exercise date. The Purchase Plan provides for two six -month purchase periods generally starting on the first trading day on or after October 31 and April 30 of each year. Eligible employees may contribute up to 15% of their eligible compensation. A participant may purchase a maximum of 2,500 shares of common stock per purchase period. The value of the shares purchased in any calendar year may not exceed $25,000 . The Purchase Plan was effective upon the completion of the Company’s IPO, at which time a total of 494,422 shares of the Company’s common stock were made available for sale. As of January 1 of each year, starting in 2011, the number of available shares will automatically be restored to the original level. A total of 82,760 and 72,261 shares of the Company’s common shares were acquired through the Purchase Plan during the years ended December 31, 2016 and 2015 , respectively. As such, on January 1, 2017 and 2016, respectively, an additional 82,760 and 72,261 shares became available for future issuance under the Purchase Plan. In accordance with ASC 718-50, the ability to purchase stock at 85% of the lower of the fair market value of a share of Common Stock on the offering date or the exercise date represents an option. The Company estimates the fair value of such options at the inception of each offering period using the Black-Scholes valuation model. In connection with the Purchase Plan, the Company recorded $80,000 and $109,000 of compensation expense for the years ended December 31, 2016 and 2015 , respectively.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The following table presents a summary of the Company ’ s reporting segments for the years ended December 31, 2016 and 2015: Year Ended U.S. International Consolidated (In thousands) NET REVENUE $ 25,765 $ 8,568 $ 34,333 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,694 ) (650 ) (2,344 ) GROSS PROFIT 24,071 7,918 31,989 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 7,875 4,500 12,375 GENERAL AND ADMINISTRATIVE EXPENSES 9,316 5,947 15,263 SALES AND MARKETING EXPENSES 22,134 7,297 29,431 DEPRECIATION AND AMORTIZATION 2,678 89 2,767 OPERATING EXPENSES 42,003 17,833 59,836 NET LOSS FROM OPERATIONS (17,932 ) (9,915 ) (27,847 ) OTHER INCOME AND EXPENSES, NET (5,155 ) NET LOSS BEFORE TAXES $ (33,002 ) Year Ended U.S. International Consolidated (In thousands) NET REVENUE $ 15,170 $ 7,268 $ 22,438 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (792 ) (970 ) (1,762 ) GROSS PROFIT 14,378 6,298 20,676 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 9,712 5,128 14,840 GENERAL AND ADMINISTRATIVE EXPENSES 8,244 5,946 14,190 SALES AND MARKETING EXPENSES 19,777 8,313 28,090 DEPRECIATION AND AMORTIZATION 2,491 64 2,555 OPERATING EXPENSES 40,224 19,451 59,675 NET LOSS FROM OPERATIONS (25,846 ) (13,153 ) (38,999 ) OTHER INCOME AND EXPENSES, NET 8,484 NET LOSS BEFORE TAXES $ (30,515 )

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) Selected quarterly financial data for years ended December 31, 2016 and 2015 are as follows (in thousands except per share data): March 31 June 30 September 30 December 31 (In thousands, except share and per share data) 2016 NET REVENUE $ 5,801 $ 9,557 $ 8,298 $ 10,677 COST OF GOOD SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (378 ) (556 ) (486 ) (924 ) GROSS PROFIT 5,423 9,001 7,812 9,753 LOSS FROM OPERATIONS (8,790 ) (6,449 ) (7,243 ) (5,365 ) NET LOSS BEFORE TAXES (11,136 ) (6,816 ) (9,212 ) (5,838 ) NET LOSS APPLICABLE TO COMMON STOCKHOLDERS (11,145 ) (6,858 ) (9,245 ) (5,926 ) NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Basic and diluted (0.25 ) (0.15 ) (0.16 ) (0.09 ) 2015 NET REVENUE $ 3,938 $ 5,776 $ 6,901 $ 5,823 COST OF GOOD SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (283 ) (376 ) (634 ) (469 ) GROSS PROFIT 3,655 5,400 6,267 5,354 LOSS FROM OPERATIONS (10,994 ) (9,800 ) (8,444 ) (9,761 ) NET LOSS BEFORE TAXES (9,793 ) (8,596 ) (1,543 ) (10,713 ) NET LOSS APPLICABLE TO COMMON STOCKHOLDERS (9,793 ) (8,596 ) (1,543 ) (10,713 ) NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Basic and diluted (0.22 ) (0.19 ) (0.03 ) (0.24 ) As a result of the Company’s weighted averages shares outstanding changing from quarter to quarter, the quarterly per share data will not necessarily add to the annual total.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates in Financial Statements	Use of Estimates in Financial Statements — The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ from those estimates.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of Alimera Sciences, Inc. and all wholly-owned subsidiaries. All significant inter-company balances have been eliminated in consolidation.
Cash and Cash Equivalents	Cash, Cash Equivalents and Restricted Cash — Cash and cash equivalents include cash and highly liquid investments that are readily convertible into cash and have a maturity of 90 days or less when purchased. Generally, cash and cash equivalents held at financial institutions are in excess of federally insured limits. The Company limits its exposure to credit loss by placing its cash and cash equivalents in highly liquid investments with high quality financial institutions. Cash and cash equivalents were $30,979,000 and $31,075,000 as of December 31, 2016 and 2015, respectively, with approximately 92.0% and 90.0% of these balances, respectively held in U.S. based financial institutions. In addition, the Company has certain credit arrangements that require the Company to maintain minimum balances in specific bank accounts as collateral which are recorded as restricted cash.
Revenue Recognition	Revenue Recognition — The Company recognizes revenue from its product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. Title passes generally upon shipment or upon receipt by the customer depending on the agreement with the customer. Precise information regarding the receipt of product by the customer is not always readily available. In these cases, the Company estimates the date of receipt based upon shipping policies by geographic location. The Company ’ s shipping policies require delivery within 24 hours of shipment in most instances. Taxes that are collected from customers and remitted to governmental authorities are not included in revenue. In the U.S., the Company sells ILUVIEN to a limited number of pharmaceutical distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the pharmaceutical distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees and other sales-related deductions. Calculating these provisions involves management’s estimates and judgments. The Company reviews its estimates of rebates, chargebacks and other applicable provisions each period and records any necessary adjustments in the current period’s net product sales. The Company estimates reductions to product sales for Medicaid and Veterans’ Administration (VA) programs and for certain other qualifying federal and state government programs. Based upon the Company’s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company’s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received and invoices received for claims from prior quarters that have not been paid. The Company’s reserves related to discounted pricing to VA, Public Health Services and other institutions (collectively qualified healthcare providers) represent the Company’s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., pharmaceutical distributors). The Company’s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company’s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the historical chargebacks that customers have already claimed. The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. The Company will accept returns for three months prior to and up to nine months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company’s products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company’s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable are generated through sales primarily to pharmacies, hospitals and wholesalers which began in 2013. The Company does not require collateral from its customers for accounts receivable. The carrying amount of accounts receivable is reduced by an allowance for doubtful accounts that reflects management ’ s best estimate of the amounts that will not be collected. In addition to reviewing delinquent accounts receivable, management considers many factors in estimating its general allowance, including historical data, experience, customer types, credit worthiness and economic trends. From time to time, management may adjust its assumptions for anticipated changes in any of those or other factors expected to affect collectability. Provisions for doubtful accounts are charged to operations at the time management determines these accounts may become uncollectable. The Company writes off accounts receivable when management determines they are uncollectable and credits payments subsequently received on such receivables to bad debt expense in the period received. The following summarizes activity related to the Company ’ s allowance for doubtful accounts:
Inventory	Inventory — Inventories are stated at the lower of cost or market with cost determined under the first in, first out (FIFO) method. Included in inventory costs are component parts, work-in-progress and finished goods. The Company relies on third party manufacturers for the production of all inventory and does not capitalize any internal costs. The Company periodically reviews inventories for excess, obsolete or expiring inventory and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated, or if there are any further determinations that inventory will not be marketable based on estimates of demand, additional inventory write-downs will be required.
Intangible Assets	Intangible Assets — The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, which approximates a straight-line basis, over the estimated periods benefited. The estimated useful life of the intangible asset is approximately thirteen years .
Property and Equipment	Property and Equipment — Property and equipment are stated at cost. Additions and improvements are capitalized while repairs and maintenance are expensed. Depreciation is provided on the straight-line method over the useful life of the related assets beginning when the asset is placed in service. The estimated useful lives of the individual assets are as follows: furniture, fixtures and manufacturing equipment, five years ; automobiles, four years ; office equipment and leasehold improvements, 29 months to five years ; and software, three years .
Impairment	Impairment — Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, the Company evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved.
Income Taxes	Income Taxes — In accordance with the Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 740, Income Taxes , the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position; therefore, no ASC 740-10 liabilities for uncertain tax positions have been recorded. The Company will recognize accrued interest and penalties related to unrecognized tax benefits, if any, as interest expense and income tax expense, respectively, in the consolidated statements of operations. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets as a result of the Company ’ s history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations.
Research and Development Costs	Research and Development Costs — Research and development costs are expensed as incurred. Research and development expenses were $2,146,000 and $2,395,000 for the years ended December 31, 2016 and 2015, respectively.
Stock-Based Compensation	Stock-Based Compensation — The Company has stock option plans which provide for grants of stock options to employees and directors to purchase shares of the Company’s common stock at exercise prices generally equal to the fair market values of such stock at the dates of grant. Compensation cost is recognized for all share-based awards based on the grant date fair value in accordance with the provisions of ASC 718, Compensation — Stock Compensation . The fair values for the options are estimated at the dates of grant using a Black-Scholes option-pricing model. Additionally, the Company sponsors an employee stock purchase plan (ESPP) under which employees may elect payroll withholdings to fund purchases of the Company’s stock at a discount. The Company estimates the fair value of the option to purchase shares of the Company’s common stock using the Black-Scholes valuation model and recognizes compensation expense in accordance with the provisions of ASC 718-50, Employee Share Purchase Plans .
Derivative Financial Instruments	Derivative Financial Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase Series A Convertible Preferred Stock or common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants were considered derivative instruments at issuance because the agreements provide for settlement in Series A Convertible Preferred Shares or common shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The warrant exercise price no longer can be adjusted at some point in the future. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of change in fair value of derivative warrant liability in the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. As of December 31, 2016 and 2015, these warrants represented the only outstanding derivative instruments issued or held by the Company.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and current assets and liabilities approximate their fair value because of their short maturities. The weighted average interest rate of the Company’s notes payable approximates the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the note approximates the fair value. The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.
Translation Policy	Translation Policy - The U.S. dollar is the functional currency for Alimera Sciences, Inc. The Euro is the functional currency for the majority of the Company ’ s subsidiaries operating outside of the U.S. For Alimera Sciences, Inc., foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for non-monetary balance sheet accounts, which are remeasured at historical exchange rates. Revenue and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the non-monetary balance sheet amounts, which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurements are included in the statement of operations. The financial statements of the foreign subsidiaries whose functional currency is not the U.S. dollar, have been translated into U.S. dollars in accordance with ASC 830-30, Translation of Financial Statements . For the subsidiaries operating outside of the U.S. that are denominated in the Euro, assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive loss.
Earnings Per Share (EPS)	Earnings Per Share (EPS) — Basic EPS is calculated in accordance with ASC 260, Earnings per Share by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants, convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Years Ended December 31, 2016 2015 Series A convertible preferred stock 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 8,416,251 Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 1,795,663 738,331 Stock options 10,804,412 9,475,890 Total 34,550,161 32,164,307
Reporting Segments	Reporting Segments — The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, U.S. and International.
Promotional and Advertising Costs	Promotional and Advertising Costs — Promotional and advertising costs are expensed as incurred.
Adoption of New Accounting Pronouncements	Adoption of New Accounting Standards — In June 2014, the FASB issued Accounting Standards Update (ASU) 2014-12, Compensation Stock - Compensation (Topic 718) . ASU 2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. It requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition and follows existing accounting guidance for the treatment of performance conditions. The standard was effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The adoption of this guidance did not have a material impact on its financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued and provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. ASU 2014-15 applies to all entities and is effective for annual and interim reporting periods ending after December 15, 2016, with early adoption permitted. The adoption of this guidance did not have a material impact on its financial statements. In April 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company elected to early adopt ASU 2015-03 effective December 31, 2015, and as a result the Company reclassified $629,000 from deferred financing costs to note payable in its Consolidated Balance Sheet as of December 31, 2015. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes , which simplifies the presentation of deferred income taxes. This ASU requires that deferred tax assets and liabilities be classified as non-current in a statement of financial position. The Company elected to early adopt ASU 2015-17 effective December 31, 2015 on a prospective basis. Adoption of this ASU resulted in a reclassification of our net current deferred tax asset to the net non-current deferred tax asset in its Consolidated Balance Sheet as of December 31, 2015. Accounting Standards Issued but Not Yet Effective — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) , as subsequently amended. ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company has begun its evaluation of the new guidance on its business and, at this time, do not believe there will be a material impact on the Company ’ s current direct product sales in international markets. For the U.S. business, the Company continues to evaluate the variable consideration provisions of the new guidance and the impact it will have specifically on the Company’s gross to net revenue adjustments, including chargebacks and rebates. The Company anticipates adopting the new revenue standard using the modified retrospective transition method. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory . This update requires entities to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those years. The Company does not expect the impact of the adoption to have a material effect on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718) . This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for interim and annual reporting periods beginning after December 15, 2016, although early adoption is permitted. The Company does not expect the impact of the adoption to have a material effect on its financial statements.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Allowances fro Doubtful Accounts	The following summarizes activity related to the Company ’ s allowance for doubtful accounts: Years Ended December 31, 2016 2015 (in thousands) Beginning balance $ 118 $ — Bad debt expense — 118 Recovery of bad debt reserve (118 ) — Ending balance $ — $ 118
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Years Ended December 31, 2016 2015 Series A convertible preferred stock 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 8,416,251 Series A convertible preferred stock warrants 4,511,279 4,511,279 Common stock warrants 1,795,663 738,331 Stock options 10,804,412 9,475,890 Total 34,550,161 32,164,307

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: December 31, 2016 2015 (In thousands) Component parts (1) $ 115 $ 131 Work-in-process (2) 18 333 Finished goods 353 1,525 Total inventory 486 1,989 Inventory reserve (40 ) (437 ) Inventory — net $ 446 $ 1,552 (1) Component parts inventory consisted of manufactured components of the ILUVIEN applicator. (2) Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EEA regulatory authorities.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: December 31, 2016 2015 (In thousands) Furniture and fixtures $ 391 $ 376 Office equipment 838 794 Automobiles 762 1,028 Software 973 902 Leasehold improvements 460 439 Manufacturing equipment 997 970 Total property and equipment 4,421 4,509 Less accumulated depreciation and amortization (2,634 ) (1,956 ) Property and equipment — net $ 1,787 $ 2,553

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Future Amortization Expense	The estimated remaining amortization as of December 31, 2016 is as follows (in thousands): Years Ending December 31 2017 $ 1,940 2018 1,940 2019 1,940 2020 1,946 2021 1,940 Thereafter 10,898 Total $ 20,604

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following: December 31, 2016 2015 (In thousands) Accrued clinical investigator expenses $ 1,122 $ 732 Accrued other compensation expenses 1,020 804 Accrued rebate, chargeback and other revenue reserves 809 452 Accrued End of Term Payment (Note 9) — 1,050 Other accrued expenses 807 873 Total accrued expenses $ 3,758 $ 3,911

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Principal Payments Under Note Payable	As of December 31, 2016 a schedule of future minimum principal payments, excluding PIK Interest and excluding the End of Term Payment of $1,400,000 which is payable in May 2018, under the Note Payable is as follows (in thousands): Years Ending December 31 (In thousands) 2017 $ — 2018 $ 1,300 2019 $ 16,526 2020 $ 17,174 Total $ 35,000
Schedule of Future Minimum Rental Payments for Operating Leases	As of December 31, 2016 , a schedule by year of future minimum payments under all of the Company’s operating leases is as follows: Years Ending December 31 (In thousands) 2017 $ 547 2018 512 2019 459 2020 350 2021 268 Total $ 2,136
Schedule by Year of Future Minimum Payments under Capital Leases, Together with Present Value of Minimum Lease Payments	As of December 31, 2016 , a schedule by year of future minimum payments under capital leases, together with the present value of minimum lease payments, is as follows (in thousands): Years Ending December 31 (In thousands) 2017 $ 300 2018 289 2019 107 2020 3 Total 699 Less amount representing interest (41 ) Less amount representing executory costs (193 ) Present value of minimum lease payments 465 Less current portion (191 ) Non-current portion $ 274
Schedule of Property and Equipment Under Capital Leases	Property and equipment under capital leases, which are included in property and equipment (Note 5), consisted of the following: December 31, 2016 2015 (In thousands) Automobiles $ 762 $ 1,028 Office equipment 63 63 Less accumulated depreciation (342 ) (212 ) Total $ 483 $ 879

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Transactions	A summary of stock option transactions under the plans are as follows: Years Ended December 31, 2016 2015 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 9,475,890 $ 3.43 7,681,256 $ 3.03 Grants 2,195,250 2.05 2,570,000 4.62 Forfeitures (581,497 ) 3.15 (431,114 ) 4.79 Exercises (285,231 ) 1.41 (344,252 ) 1.66 Options outstanding at year end 10,804,412 3.22 9,475,890 3.43 Options exercisable at year end 7,363,400 3.29 5,808,528 3.27 Weighted average per share fair value of options granted during the year $ 1.55 $ 3.58
Summary of Additional Stock Option Transactions	The following table provides additional information related to outstanding stock options, fully vested stock options, and stock options expected to vest as of December 31, 2016 : Shares Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 10,804,412 $ 3.22 6.45 years $ — Exercisable 7,363,400 3.29 5.42 years — Outstanding, vested and expected to vest 10,374,846 3.23 6.35 years —
Weighted-Average Assumptions Used for Option Grants	The weighted-average assumptions used for option grants were as follows: Years Ended December 31, 2016 2015 Risk-free interest rate 1.57 % 1.55 % Volatility factor 93.54 % 96.80 % Grant date fair value of common stock options $ 1.55 $ 3.58 Weighted-average expected life 5.99 years 6.03 years Assumed forfeiture rate 10.00 % 10.00 %
Employee Stock-Based Compensation Expense	Employee stock-based compensation expense related to stock options recognized in accordance with ASC 718 was as follows: Years Ended December 31, 2016 2015 (In thousands) Sales and marketing $ 1,109 $ 925 Research, development and medical affairs 886 1,271 General and administrative 2,814 2,732 Total employee stock-based compensation expense $ 4,809 $ 4,928

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Components of Net Loss before Taxes	The components of net loss before taxes are as follows: Years Ended December 31, 2016 2015 (In thousands) United States $ (8,516 ) $ (6,026 ) Foreign (24,486 ) (24,489 ) Loss before provision for income taxes $ (33,002 ) $ (30,515 )
Components of Income Tax Benefit	The provision for income taxes consists of the following components: Years Ended December 31, 2016 2015 (In thousands) Current expense (benefit): Federal $ — $ — State — — Foreign 385 353 Current income tax expense 385 353 Deferred expense (benefit): Federal 3,099 6,509 State (858 ) 819 Foreign (213 ) (223 ) 2,028 7,105 Valuation allowance (2,241 ) (7,328 ) Deferred income tax benefit (213 ) (223 ) Total income tax expense $ 172 $ 130
Summary of Valuation Allowance	The following summarizes activity related to the Company ’ s valuation allowance: Years Ended December 31, 2016 2015 (In thousands) Valuation allowance at beginning of period $ (53,727 ) $ (46,399 ) Income tax provision (2,241 ) (7,328 ) Release of valuation allowance — — Other — — Valuation allowance at end of period $ (55,968 ) $ (53,727 )
Net Deferred Tax Assets (Liabilities)	Worldwide net deferred tax assets and liabilities are as follows: December 31, 2016 2015 Deferred tax assets (In thousands) Depreciation and amortization $ 12 $ 3 Other deferred tax assets 5,824 4,643 NOL carry-forwards 38,183 36,941 Research and development costs 3,063 4,193 Collaboration agreement receivable reserves 9,327 8,186 Valuation allowance (55,968 ) (53,727 ) Total deferred tax assets $ 441 $ 239 Deferred tax liabilities Unrealized foreign currency gains $ — $ (12 ) Other deferred tax liabilities (5 ) (4 ) Total deferred tax liabilities (5 ) (16 ) Net deferred tax assets and deferred tax liabilities $ 436 $ 223
Reconciliation of Income Tax Benefit to Amount Determined by Applying U.S. Federal Statutory Income Tax Rate	A reconciliation from the federal statutory rate to the total provision for income taxes is as follows: Years Ended December 31, 2016 2015 Amount Percent Amount Percent Federal tax benefit at statutory rate $ (11,219 ) 34.0 % $ (10,375 ) 34.0 % State tax — net of federal benefit (10 ) — (715 ) 2.4 Permanent items and other (225 ) 0.7 (3,997 ) 13.1 Prior period transfer pricing adjustments — — — — Foreign rate differential 8,470 (26.1 ) 8,352 (27.4 ) Deferred rate change 825 (2.5 ) — — Other 90 (0.3 ) (463 ) 1.5 Change in valuation allowance 2,241 (6.3 ) 7,328 (24.0 ) Total tax expense (benefit) $ 172 (0.5 )% $ 130 (0.4 )%
Uncertain Tax Positions Rollforward	A rollforward of the Company’s uncertain tax positions is as follows: Years Ended December 31, 2016 2015 (In thousands) Balance of uncertain tax positions at beginning of period $ 46 $ — Gross increases - tax positions in current period 16 3 Gross increases - tax positions in prior period 13 43 Gross decreases - tax positions in prior period (16 ) — Settlements — — Lapse of statute of limitations — — Balance of uncertain tax positions at end of period $ 59 $ 46

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: December 31, 2016 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ — $ — $ — $ — Assets measured at fair value $ — $ — $ — $ — Liabilities: Derivative warrant liability (2) $ — $ 188 $ — $ 188 Liabilities measured at fair value $ — $ 188 $ — $ 188 December 31, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 1,010 $ — $ — $ 1,010 Assets measured at fair value $ 1,010 $ — $ — $ 1,010 Liabilities: Derivative warrant liability (2) $ — $ 2,815 $ — $ 2,815 Liabilities measured at fair value $ — $ 2,815 $ — $ 2,815 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Reporting Segments	The following table presents a summary of the Company ’ s reporting segments for the years ended December 31, 2016 and 2015: Year Ended U.S. International Consolidated (In thousands) NET REVENUE $ 25,765 $ 8,568 $ 34,333 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,694 ) (650 ) (2,344 ) GROSS PROFIT 24,071 7,918 31,989 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 7,875 4,500 12,375 GENERAL AND ADMINISTRATIVE EXPENSES 9,316 5,947 15,263 SALES AND MARKETING EXPENSES 22,134 7,297 29,431 DEPRECIATION AND AMORTIZATION 2,678 89 2,767 OPERATING EXPENSES 42,003 17,833 59,836 NET LOSS FROM OPERATIONS (17,932 ) (9,915 ) (27,847 ) OTHER INCOME AND EXPENSES, NET (5,155 ) NET LOSS BEFORE TAXES $ (33,002 ) Year Ended U.S. International Consolidated (In thousands) NET REVENUE $ 15,170 $ 7,268 $ 22,438 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (792 ) (970 ) (1,762 ) GROSS PROFIT 14,378 6,298 20,676 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 9,712 5,128 14,840 GENERAL AND ADMINISTRATIVE EXPENSES 8,244 5,946 14,190 SALES AND MARKETING EXPENSES 19,777 8,313 28,090 DEPRECIATION AND AMORTIZATION 2,491 64 2,555 OPERATING EXPENSES 40,224 19,451 59,675 NET LOSS FROM OPERATIONS (25,846 ) (13,153 ) (38,999 ) OTHER INCOME AND EXPENSES, NET 8,484 NET LOSS BEFORE TAXES $ (30,515 )

Selected Quarterly Financial 38

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Selected quarterly financial data for years ended December 31, 2016 and 2015 are as follows (in thousands except per share data): March 31 June 30 September 30 December 31 (In thousands, except share and per share data) 2016 NET REVENUE $ 5,801 $ 9,557 $ 8,298 $ 10,677 COST OF GOOD SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (378 ) (556 ) (486 ) (924 ) GROSS PROFIT 5,423 9,001 7,812 9,753 LOSS FROM OPERATIONS (8,790 ) (6,449 ) (7,243 ) (5,365 ) NET LOSS BEFORE TAXES (11,136 ) (6,816 ) (9,212 ) (5,838 ) NET LOSS APPLICABLE TO COMMON STOCKHOLDERS (11,145 ) (6,858 ) (9,245 ) (5,926 ) NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Basic and diluted (0.25 ) (0.15 ) (0.16 ) (0.09 ) 2015 NET REVENUE $ 3,938 $ 5,776 $ 6,901 $ 5,823 COST OF GOOD SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (283 ) (376 ) (634 ) (469 ) GROSS PROFIT 3,655 5,400 6,267 5,354 LOSS FROM OPERATIONS (10,994 ) (9,800 ) (8,444 ) (9,761 ) NET LOSS BEFORE TAXES (9,793 ) (8,596 ) (1,543 ) (10,713 ) NET LOSS APPLICABLE TO COMMON STOCKHOLDERS (9,793 ) (8,596 ) (1,543 ) (10,713 ) NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS - Basic and diluted (0.22 ) (0.19 ) (0.03 ) (0.24 )

Nature of Operations (Detail)

Nature of Operations (Detail) - ILUVIEN	12 Months Ended
	Dec. 31, 2016Patient
Nature Of Operations [Line Items]
Post-authorization open study period	5 years
Maximum number of patients involved in post-authorization open study period	800
Number of patients involved in post-authorization open study period	548

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Prior Period Adjustments (Details) - Effect of early adoption $ in Thousands	Dec. 31, 2015USD ($)
Deferred Financing Costs
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance costs	$ (629)
Notes Payable
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance costs	$ (629)

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Accounting Policies [Abstract]
Cash and cash equivalents	$ 30,979	$ 31,075	$ 76,697
Percentage of cash and cash equivalents in domestic financial institutions	92.00%	90.00%
Useful life of intangible assets	13 years
Research and development expense	$ 2,146	$ 2,395
Number of reportable segments | Segment	2

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Long Lived Assets (Details)	12 Months Ended
	Dec. 31, 2016
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Automobiles
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Office equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	29 months
Office equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Software
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Allowances for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance	$ 118	$ 0
Bad debt expense	0	118
Recovery of bad debt reserve	(118)	0
Ending balance	$ 0	$ 118

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Securities Not Included in Computation of Diluted EPS (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	34,550,161	32,164,307
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	9,022,556	9,022,556
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	8,416,251	8,416,251
Series A convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	4,511,279	4,511,279
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	1,795,663	738,331
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities (in shares)	10,804,412	9,475,890

Going Concern (Detail)

Going Concern (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (377,074)	$ (343,900)
Cash and cash equivalents	30,979	$ 31,075	$ 76,697
Capital shares reserved for future issuance	$ 22,000

Inventory (Detail)

Inventory (Detail) - USD ($) $ in Thousands		Dec. 31, 2016	Dec. 31, 2015
Inventory net realizable value
Component parts (1)	[1]	$ 115	$ 131
Work-in-process (2)	[2]	18	333
Finished goods		353	1,525
Total inventory		486	1,989
Inventory reserve		(40)	(437)
Inventory — net		$ 446	$ 1,552
[1]	Component parts inventory consisted of manufactured components of the ILUVIEN applicator.
[2]	Work-in-process consisted of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by U.S. or EEA regulatory authorities.

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 4,421	$ 4,509
Less accumulated depreciation and amortization	(2,634)	(1,956)
Property and equipment — net	1,787	2,553
Depreciation expense	822	614
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	391	376
Office equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	838	794
Automobiles
Property, Plant and Equipment [Line Items]
Total property and equipment	762	1,028
Software
Property, Plant and Equipment [Line Items]
Total property and equipment	973	902
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	460	439
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 997	$ 970

Intangible Assets - Activity (D

Intangible Assets - Activity (Details) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Useful life		13 years
Intangible assets, net		$ 20,604,000
Licensing Agreement
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		$ 25,000,000
Useful life		13 years
Intangible assets, net		$ 20,604,000	$ 22,549,000
Intangible asset amortization expense		$ 1,946,000	$ 1,940,000
pSivida
Finite-Lived Intangible Assets [Line Items]
Additional milestone payment after the first product approved by the FDA	$ 25,000,000

Intangible Assets - Future Amor

Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2016USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,017	$ 1,940
2,018	1,940
2,019	1,940
2,020	1,946
2,021	1,940
Thereafter	10,898
Total	$ 20,604

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Summary of accrued expenses
Accrued clinical investigator expenses	$ 1,122	$ 732
Accrued other compensation expenses	1,020	804
Accrued rebate, chargeback and other revenue reserves	809	452
Accrued End of Term Payment (Note 9)	0	1,050
Other accrued expenses	807	873
Total accrued expenses	$ 3,758	$ 3,911

License Agreements (Details)

License Agreements (Details) - pSivida - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Minimum days to require to revert license in case of breaches of contract		30 days
Maximum days to require to revert license in case of breaches of contract		90 days
Period of bankruptcy petition proceedings remains undismissed		60 days
Share of net profits		20.00%
Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN		33.00%
Recovery of commercialization costs		20.00%
Commercialization costs owned		$ 25,828,000		$ 21,565,000
Additional milestone payment after the first product approved by the FDA	$ 25,000,000
Payment for portion of net profits		240,000
Commercialization cost disputed by licensor			$ 1,290,000
Commercialization costs receivable		25,828,000	12,956,000	21,565,000
Collaborative arrangement incremental profit sharing payments			$ 136,000
Commercialization cost receivable post adjustment		$ 21,201,000		$ 18,504,000

Loan Agreements Narrative (Deta

Loan Agreements Narrative (Details)	1 Months Ended				12 Months Ended
	Oct. 31, 2016USD ($)payment$ / sharesshares	Aug. 31, 2016USD ($)	Nov. 30, 2015USD ($)$ / sharesshares	Apr. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jul. 31, 2016USD ($)$ / sharesshares	May 31, 2016USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2014USD ($)
Debt Instrument [Line Items]
Balloon payment to be paid					$ 0	$ 1,050,000
Loss on early extinguishment of debt					2,564,000	0
Payments of debt issuance costs					$ 1,069,000	$ 264,000
Alimera Sciences Limited | 2014 Term Loan | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Company entitled to borrow				$ 35,000,000
Term loan amount				$ 10,000,000						$ 25,000,000
Interest rate on term loan (percent)				10.90%
Interest rate on Term Loan Agreement					11.25%
Alimera Sciences Limited | 2014 Term Loan | Hercules Technology Growth Capital | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percent)				7.65%
Alimera Sciences Limited | First Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Upfront fee payment to Lenders			$ 263,000
Balloon payment to be paid			$ 1,050,000
Balloon payment, percent of principal			3.00%
Alimera Sciences Limited | Second Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Upfront fee payment to Lenders									$ 350,000
Balloon payment to be paid									$ 1,400,000
Loss on early extinguishment of debt					$ 2,564,000
Payments of debt issuance costs					360,000
Alimera Sciences Limited | Third Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Minimum required cash balance per covenant								$ 2,000,000
Alimera Sciences Limited | July 2016 Waiver | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Upfront fee payment to Lenders							$ 350,000
Weekly ticking fee (percent)							0.05%
Ticking fee		$ 65,000
Alimera Sciences Limited | Fourth Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Interest rate on term loan (percent)	11.00%
Upfront fee payment to Lenders	$ 338,000
Increase in borrowing capacity	$ 10,000,000
Payment-in-kind interest rate	1.00%
Number of monthly payments | payment	24
Prepayment fee percentage within the first year of borrowing	3.00%
Prepayment fee percentage within the second year of borrowing	2.00%
Prepayment fee percentage after the second year of borrowing and thereafter	1.00%
Minimum liquidity threshold per covenant	$ 35,000,000
Current liquidity per covenant					40,923,000
Current cash and cash equivalents liquidity per covenant					30,979,000
Current accounts receivable liquidity per covenant					$ 12,430,000
Number of shares called by warrants | shares	458,716
Exercise price on warrants (in dollars per share) | $ / shares	$ 1.09
Alimera Sciences Limited | Fourth Loan Amendment | Hercules Technology Growth Capital | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percent)	11.00%
Reduction in basis spread on variable rate	3.50%
Alimera Sciences, Inc. | 2014 Term Loan | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Term loan amount										$ 25,000,000
Number of shares called by warrants | shares				285,016
Exercise price on warrants (in dollars per share) | $ / shares				$ 6.14
Percent of warrants exercisable upon closing				60.00%
Percent of warrants exercisable upon satisfying certain conditions				40.00%
Alimera Sciences, Inc. | First Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Number of shares called by warrants | shares			660,377
Exercise price on warrants (in dollars per share) | $ / shares			$ 2.65
Alimera Sciences, Inc. | Second Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Number of shares called by warrants | shares									862,069
Exercise price on warrants (in dollars per share) | $ / shares									$ 2.03
Alimera Sciences, Inc. | July 2016 Waiver | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Number of shares called by warrants | shares							1,258,993
Exercise price on warrants (in dollars per share) | $ / shares							$ 1.39
Tranche One | Alimera Sciences Limited | Fourth Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Increase in borrowing capacity	$ 5,000,000
Revenue requirement	12,000,000
Tranche Two | Alimera Sciences Limited | Fourth Loan Amendment | Hercules Technology Growth Capital
Debt Instrument [Line Items]
Increase in borrowing capacity	5,000,000
Revenue requirement	$ 15,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jan. 01, 2016USD ($)Employee	May 31, 2013Patientcontract	Feb. 28, 2010	Dec. 31, 2016USD ($)PatientEmployee	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)agreement	May 31, 2018USD ($)
Commitments and Contingencies [Line Items]
Accrued and unpaid interest payable on Note Payable				$ 336,000	$ 333,000	$ 336,000
Balloon payment to be paid				0	1,050,000	0
Rent expense under all operating leases				544,000	541,000
Depreciation expense				$ 822,000	614,000
Percentage of order of ILUVIEN units required			80.00%
Agreement period			6 years
Renewal option additional period			1 year
Prior written notice period			12 months
Number of executives in employment agreements | Employee	5			5
Minimum
Commitments and Contingencies [Line Items]
Executives salaries	$ 253,000
Maximum
Commitments and Contingencies [Line Items]
Executives salaries	$ 519,000
CRO Agreement, physician utilization study
Commitments and Contingencies [Line Items]
Clinical and data management services expense				$ 157,000	591,000
Outsourced services payable				76,000	150,000	76,000
Clinical and data management services expense expected to be incurred				587,000		587,000
Quintiles Commercial Europe Limited
Commitments and Contingencies [Line Items]
Clinical and data management services expense				0	1,030,000
Outsourced services payable				164,000	170,000	$ 164,000
Capital leased assets
Commitments and Contingencies [Line Items]
Depreciation expense				$ 267,000	$ 210,000
ILUVIEN
Commitments and Contingencies [Line Items]
Post-authorization open study period				5 years
Number of patients involved in post-authorization open study period | Patient				800
ILUVIEN | CRO Agreement, physician utilization study
Commitments and Contingencies [Line Items]
Number of contract research organizations engaged | contract		3
Post-authorization open study period		5 years
Number of patients involved in post-authorization open study period | Patient		800
Number of agreements for clinical and data management services | agreement						9
Scenario, Forecast
Commitments and Contingencies [Line Items]
Balloon payment to be paid							$ 1,400,000

Commitments and Contingencies54

Commitments and Contingencies - Schedule of Future Minimum Principal Payments Under Note Payable (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2,018	$ 1,300
2,019	16,526
2,020	17,174
Total	$ 35,000

Commitments and Contingencies55

Commitments and Contingencies - Schedule of Operating Lease Assets (Details) $ in Thousands	Dec. 31, 2016USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,017	$ 547
2,018	512
2,019	459
2,020	350
2,021	268
Total	$ 2,136

Commitments and Contingencies56

Commitments and Contingencies - Schedule by Year of Future Minimum Payments under Capital Leases, Together with Present Value of Minimum Lease Payments (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,017	$ 300
2,018	289
2,019	107
2,020	3
Total	699
Less amount representing interest	(41)
Less amount representing executory costs	(193)
Present value of minimum lease payments	465
Less current portion	(191)	$ (234)
Non-current portion	$ 274	$ 582

Commitments and Contingencies57

Commitments and Contingencies - Property and Equipment Under Capital Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Capital Leased Assets [Line Items]
Less accumulated depreciation	$ (342)	$ (212)
Total	483	879
Automobiles
Capital Leased Assets [Line Items]
Gross capital leased assets	762	1,028
Office equipment
Capital Leased Assets [Line Items]
Gross capital leased assets	$ 63	$ 63

Preferred Stock (Detail)

Preferred Stock (Detail) - USD ($)	Dec. 12, 2014	Oct. 02, 2012	Sep. 30, 2014	Apr. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Estimated fair value of derivatives					$ 188,000	$ 2,815,000
Gain (loss) on change in fair value of derivatives					2,627,000	13,283,000
Stock issuance costs incurred					$ 1,341,000	$ 27,000
Series A convertible preferred stock
Class of Stock [Line Items]
Number of preferred stock and warrants.		1,000,000
Warrants to purchase additional shares		300,000
Gross proceeds under securities purchase agreement		$ 40,000,000
Estimated total stock issuance cost		$ 560,000
Gross proceeds under securities purchase agreement per value		$ 40
Initial conversion price subjected to adjustment two (in dollars per share)		2.66
Preferred stock converted to common stock per share (in dollars per share)		$ 10
Proceeds from issuance of preferred stock		$ 30,000,000
Proportion of each unit of shares (in shares)		0.30
Exercise price of warrants (in dollars per share)		$ 44
Shares converted (in shares)			250,000	150,000
Common Stock
Class of Stock [Line Items]
Shares issued in conversion of preferred stock (in shares)			3,759,398	2,255,639
Series B convertible preferred stock
Class of Stock [Line Items]
Issuance of preferred stock (in shares)	8,291.873
Issuance of preferred stock (in dollars per share)	$ 6,030
Issuance of preferred stock	$ 50,000,000
Stock issuance costs incurred	$ 432,000
Common stock issued upon conversion (per preferred share)	1,000
Ownership interest of holders after conversion of preferred stock (percent)	9.98%
Intrinsic value of beneficial conversion feature							$ 750,000
Series B convertible preferred stock | Over-Allotment Option
Class of Stock [Line Items]
Issuance of preferred stock (in shares)	124.378

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term		5 years 4 months 30 days
Total estimated fair value of options granted		$ 3,410	$ 9,172
Total estimated intrinsic value of options exercised		$ 65	$ 568
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Contractual term		10 years
Total unrecognized compensation cost related to outstanding stock option awards		$ 7,049
Total unrecognized compensation cost related to outstanding stock option awards, recognition period (in years)		2 years 4 months 7 days
Total fair value of shares vested during period		$ 4,955
Directors Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Contractual term		10 years
2010 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares the company is authorized to grant		668,830
Additional shares that became available for future issuance				2,000,000
Percentage of outstanding common stock, maximum				4.00%
Subsequent event | 2010 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares that became available for future issuance	2,000,000

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock Option Transactions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options
Options outstanding at beginning of period (in shares)	9,475,890	7,681,256
Grants (in shares)	2,195,250	2,570,000
Forfeitures (in shares)	(581,497)	(431,114)
Exercises (in shares)	(285,231)	(344,252)
Options outstanding at year end (in shares)	10,804,412	9,475,890
Options exercisable at year end (in shares)	7,363,400	5,808,528
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 1.55	$ 3.58
Weighted Average Exercise Price
Options outstanding at beginning of period (in dollars per share)	3.43	3.03
Grants (in dollars per share)	2.05	4.62
Forfeitures (in dollars per share)	3.15	4.79
Exercises (in dollars per share)	1.41	1.66
Options outstanding at year end (in dollars per share)	3.22	3.43
Options exercisable at year end (in dollars per share)	$ 3.29	$ 3.27

Stock Incentive Plans - Addit61

Stock Incentive Plans - Additional Stock Option Transactions (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding, Shares	10,804,412	9,475,890	7,681,256
Exercisable, Shares	7,363,400	5,808,528
Outstanding, vested and expected to vest, Shares	10,374,846
Outstanding, weighted average exercise price (in dollars per share)	$ 3.22	$ 3.43	$ 3.03
Exercisable, weighted average exercise price (in dollars per share)	3.29	$ 3.27
Outstanding, vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 3.23
Outstanding, weighted average contractual term	6 years 5 months 12 days
Exercisable, weighted average contractual term	5 years 4 months 30 days
Outstanding, vested and expected to vest, Weighted Average Contractual Term	6 years 4 months 5 days
Outstanding, aggregate intrinsic value	$ 0
Exercisable, aggregate intrinsic value	0
Outstanding, vested and expected to vest, Aggregate Intrinsic Value	$ 0

Stock Incentive Plans - Weighte

Stock Incentive Plans - Weighted-Average Assumptions Used for Option Grants (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate (percent)	1.57%	1.55%
Volatility factor (percent)	93.54%	96.80%
Grant date fair value of common stock options (in dollars per share)	$ 1.55	$ 3.58
Weighted-average expected life	5 years 11 months 27 days	6 years 10 days
Assumed forfeiture rate (percent)	10.00%	10.00%

Stock Incentive Plans - Employe

Stock Incentive Plans - Employee Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 4,809	$ 4,928
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	1,109	925
Research, development and medical affairs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	886	1,271
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 2,814	$ 2,732

Stock Incentive Plans - Outstan

Stock Incentive Plans - Outstanding and Exercisable Options (Detail)	12 Months Ended
	Dec. 31, 2016$ / shares
$1.33 - $1.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	$ 1.33
Exercise price upper limit (in dollars per share)	1.99
$2.00 - $2.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	2
Exercise price upper limit (in dollars per share)	2.99
$3.00 - $4.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	3
Exercise price upper limit (in dollars per share)	4.99
$5.00 - $5.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	5
Exercise price upper limit (in dollars per share)	5.99
$6.00 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	6
Exercise price upper limit (in dollars per share)	10.99
$11.00 - $11.91
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price lower limit (in dollars per share)	11
Exercise price upper limit (in dollars per share)	$ 11.91

Common Stock Warrants (Detail)

Common Stock Warrants (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Oct. 31, 2016	Jul. 31, 2016	Dec. 31, 2015	Nov. 30, 2015	Sep. 30, 2014	Apr. 30, 2014
Class of Warrant or Right [Line Items]
Warrants to purchase common stock issued and outstanding (in shares)	1,795,663			738,331
Minimum
Class of Warrant or Right [Line Items]
Warrants to purchase common, exercise prices (in dollars per share)	$ 1.09
Warrants, exercisable period from issuance date	5 years
Maximum
Class of Warrant or Right [Line Items]
Warrants to purchase common, exercise prices (in dollars per share)	$ 11
Warrants, exercisable period from issuance date	10 years
2014 Term Loan | Hercules | Alimera Sciences, Inc.
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)							285,016
Exercise price on warrants (in dollars per share)							$ 6.14
Percent of warrants exercisable upon closing							60.00%
Percent of warrants exercisable upon satisfying certain conditions							40.00%
Term loan amount						$ 25,000,000
2014 Term Loan | Hercules | Alimera Sciences Limited
Class of Warrant or Right [Line Items]
Term loan amount						$ 25,000,000	$ 10,000,000
First Loan Amendment | Hercules | Alimera Sciences, Inc.
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)					660,377
Exercise price on warrants (in dollars per share)					$ 2.65
July 2016 Waiver | Hercules | Alimera Sciences, Inc.
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)			1,258,993
Exercise price on warrants (in dollars per share)			$ 1.39
Fourth Loan Amendment | Hercules | Alimera Sciences Limited
Class of Warrant or Right [Line Items]
Warrants to purchase Company's common stock, granted during period (in shares)		458,716
Exercise price on warrants (in dollars per share)		$ 1.09

Concentrations and Credit Risk

Concentrations and Credit Risk (Details) - customer	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, number of customers	2
Concentration risk percentage	75.00%	68.00%
Accounts receivable | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, number of customers		2
Concentration risk percentage	90.00%	88.00%
Purchases | Supplier concentration risk
Concentration Risk [Line Items]
Concentration risk, number of vendors	0	0

Income Taxes - Components of Ne

Income Taxes - Components of Net Loss before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
United States	$ (8,516)	$ (6,026)
Foreign	(24,486)	(24,489)
Loss before provision for income taxes	$ (33,002)	$ (30,515)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	$ 0	$ 0
State	0	0
Foreign	385	353
Current income tax expense	385	353
Deferred benefit (expense):
Federal	3,099	6,509
State	(858)	819
Foreign	(213)	(223)
Deferred benefit (expense), gross	2,028	7,105
Valuation allowance	(2,241)	(7,328)
Deferred income tax benefit	(213)	(223)
Total income tax expense	$ 172	$ 130

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance Rollforward (Details) - Deferred Tax Asset Valuation Allowance - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ (53,727)	$ (46,399)
Income tax provision	(2,241)	(7,328)
Release of valuation allowance	0	0
Other	0	0
Ending balance	$ (55,968)	$ (53,727)

Income Taxes - Net Deferred Tax

Income Taxes - Net Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets
Depreciation and amortization	$ 12	$ 3
Other deferred tax assets	5,824	4,643
NOL carry-forwards	38,183	36,941
Research and development costs	3,063	4,193
Collaboration agreement receivable reserves	9,327	8,186
Valuation allowance	(55,968)	(53,727)
Total deferred tax assets	441	239
Deferred tax liabilities
Unrealized foreign currency gains	0	(12)
Other deferred tax liabilities	(5)	(4)
Total deferred tax liabilities	(5)	(16)
Net deferred tax assets and deferred tax liabilities	$ 436	$ 223

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Benefit to Amount Determined by Applying U.S. Federal Statutory Income Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Amount
Federal tax benefit at statutory rate	$ (11,219)	$ (10,375)
State tax — net of federal benefit	(10)	(715)
Permanent items and other	(225)	(3,997)
Prior period transfer pricing adjustments	0	0
Foreign rate differential	8,470	8,352
Other	90	(463)
Change in valuation allowance	2,241	7,328
Total income tax expense	$ 172	$ 130
Percent
Federal tax benefit at statutory rate	34.00%	34.00%
State tax — net of federal benefit	0.00%	2.40%
Permanent items and other	0.70%	13.10%
Prior period transfer pricing adjustments	0.00%	0.00%
Foreign rate differential	(26.10%)	(27.40%)
Other	(0.30%)	1.50%
Change in valuation allowance	(6.30%)	(24.00%)
Total tax expense (benefit)	(0.50%)	(0.40%)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent	(2.50%)	0.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount	$ 825	$ 0

Income Taxes - Uncertain Tax Po

Income Taxes - Uncertain Tax Positions Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, beginning balance	$ 46	$ 0
Gross increases - tax positions in current period	16	3
Gross increases - tax positions in prior period	13	43
Gross decreases - tax positions in prior period	(16)	0
Settlements	0	0
Lapse of statute of limitations	0	0
Unrecognized tax benefits, ending balance	$ 59	$ 46

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Stock option expense	$ 517
Unrecognized tax benefits	59	$ 46	$ 0
Cumulative book losses in foreign subsidiaries	(92,939)
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	104,944	100,844
State
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 83,270	$ 84,301

Fair Value (Detail)

Fair Value (Detail) - Recurring basis - USD ($) $ in Thousands		Dec. 31, 2016	Dec. 31, 2015
Assets:
Cash equivalents	[1]	$ 0	$ 1,010
Assets measured at fair value		0	1,010
Liabilities:
Derivative warrant liability	[2]	188	2,815
Liabilities measured at fair value		188	2,815
Level 1
Assets:
Cash equivalents	[1]	0	1,010
Assets measured at fair value		0	1,010
Liabilities:
Derivative warrant liability	[2]	0	0
Liabilities measured at fair value		0	0
Level 2
Assets:
Cash equivalents	[1]	0	0
Assets measured at fair value		0	0
Liabilities:
Derivative warrant liability	[2]	188	2,815
Liabilities measured at fair value		188	2,815
Level 3
Assets:
Cash equivalents	[1]	0	0
Assets measured at fair value		0	0
Liabilities:
Derivative warrant liability	[2]	0	0
Liabilities measured at fair value		$ 0	$ 0
[1]	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
[2]	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock based compensation (see Note 12).

Employee Benefit Plans (Detail)

Employee Benefit Plans (Detail)	Jan. 01, 2017shares	Jan. 01, 2016shares	Apr. 30, 2010USD ($)periodshares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares
Defined Benefit Plan Disclosure [Line Items]
Compensation expense associated with the Company's matching plan | $				$ 287,000	$ 268,000
Annual discretionary profit-sharing contribution | $				0	0
Compensation expense recorded in connection with the Purchase Plan | $				$ 4,889,000	$ 5,037,000
Employee stock purchase plan
Defined Benefit Plan Disclosure [Line Items]
Purchase price of stock under ESPP as a percentage of fair market value of common stock			85.00%	85.00%
Employee stock purchase plan, number of purchase periods | period			2
Employee stock purchase plan, purchase period			6 months
Percentage of eligible compensation that may be contributed towards ESPP			15.00%
Maximum number of shares of common stock a participant may purchase per purchase period | shares			2,500
Maximum value of shares of common stock a participant may purchase in any calendar year | $			$ 25,000
Common stock, available for sale under employee stock purchase plan | shares				494,422
Common shares acquired through employee stock purchase plan | shares				82,760	72,261
Additional shares that became available for future issuance under the Purchase Plan | shares		72,261
Compensation expense recorded in connection with the Purchase Plan | $				$ 80,000	$ 109,000
Employee stock purchase plan | Subsequent event
Defined Benefit Plan Disclosure [Line Items]
Additional shares that became available for future issuance under the Purchase Plan | shares	82,760

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
NET REVENUE	$ 10,677	$ 8,298	$ 9,557	$ 5,801	$ 5,823	$ 6,901	$ 5,776	$ 3,938	$ 34,333	$ 22,438
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(924)	(486)	(556)	(378)	(469)	(634)	(376)	(283)	(2,344)	(1,762)
GROSS PROFIT	9,753	7,812	9,001	5,423	5,354	6,267	5,400	3,655	31,989	20,676
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES									12,375	14,840
GENERAL AND ADMINISTRATIVE EXPENSES									15,263	14,190
SALES AND MARKETING EXPENSES									29,431	28,090
DEPRECIATION AND AMORTIZATION									2,767	2,555
OPERATING EXPENSES									59,836	59,675
NET LOSS FROM OPERATIONS	$ (5,365)	$ (7,243)	$ (6,449)	$ (8,790)	$ (9,761)	$ (8,444)	$ (9,800)	$ (10,994)	(27,847)	(38,999)
OTHER INCOME AND EXPENSES, NET									(5,155)	8,484
NET LOSS BEFORE TAXES									(33,002)	(30,515)
U.S.
Segment Reporting Information [Line Items]
NET REVENUE									25,765	15,170
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION									(1,694)	(792)
GROSS PROFIT									24,071	14,378
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES									7,875	9,712
GENERAL AND ADMINISTRATIVE EXPENSES									9,316	8,244
SALES AND MARKETING EXPENSES									22,134	19,777
DEPRECIATION AND AMORTIZATION									2,678	2,491
OPERATING EXPENSES									42,003	40,224
NET LOSS FROM OPERATIONS									(17,932)	(25,846)
International
Segment Reporting Information [Line Items]
NET REVENUE									8,568	7,268
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION									(650)	(970)
GROSS PROFIT									7,918	6,298
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES									4,500	5,128
GENERAL AND ADMINISTRATIVE EXPENSES									5,947	5,946
SALES AND MARKETING EXPENSES									7,297	8,313
DEPRECIATION AND AMORTIZATION									89	64
OPERATING EXPENSES									17,833	19,451
NET LOSS FROM OPERATIONS									$ (9,915)	$ (13,153)

Selected Quarterly Financial 77

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
NET REVENUE	$ 10,677	$ 8,298	$ 9,557	$ 5,801	$ 5,823	$ 6,901	$ 5,776	$ 3,938	$ 34,333	$ 22,438
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(924)	(486)	(556)	(378)	(469)	(634)	(376)	(283)	(2,344)	(1,762)
GROSS PROFIT	9,753	7,812	9,001	5,423	5,354	6,267	5,400	3,655	31,989	20,676
NET LOSS FROM OPERATIONS	(5,365)	(7,243)	(6,449)	(8,790)	(9,761)	(8,444)	(9,800)	(10,994)	(27,847)	(38,999)
NET LOSS	(5,838)	(9,212)	(6,816)	(11,136)	(10,713)	(1,543)	(8,596)	(9,793)	$ (33,174)	$ (30,645)
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS	$ (5,926)	$ (9,245)	$ (6,858)	$ (11,145)	$ (10,713)	$ (1,543)	$ (8,596)	$ (9,793)
NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS — Basic and diluted (in dollars per share)	$ (0.09)	$ (0.16)	$ (0.15)	$ (0.25)	$ (0.24)	$ (0.03)	$ (0.19)	$ (0.22)	$ (0.63)	$ (0.69)